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Abstract 
 
Novel serum biomarkers for lung cancer early diagnosis and clinical outcome 
Fanmao Zhang, B.S. 
Advisory Professor: Xifeng Wu, M.D., Ph.D. 
The five-year survival rate for all stages of lung cancer combined is only 
17%, which has changed little over the past 40 years. Despite the tremendous 
efforts made, serum biomarkers with clinical utility for lung cancer early detection 
and clinical outcome prediction are still lacking. Metabolic alterations have been 
recognized as an emerging hallmark of cancer. We aimed to investigate the 
metabolic changes associated with lung cancer and to identify novel clinically 
applicable serum biomarkers for lung cancer early diagnosis and clinical outcome. 
Serum metabolites are potential biomarkers for lung cancer early detection. 
We first performed global metabolomic profiling followed by targeted validation of 
individual metabolites in a case-control design of 386 lung cancer cases and 193 
matched controls. We then validated the most significant metabolite bilirubin as a 
risk marker for lung cancer incidence and mortality in a large prospective cohort 
comprised of 425,660 participants. In this cohort, the inverse association was only 
seen in male smokers. For every 0.1 mg/dL decrease of bilirubin, the risks for lung 
cancer incidence and mortality increased by 5% and 6%, respectively (both P < 
0.001).  
We next investigated pre-treatment laboratory tests indicative of a patient’s 
overall metabolic status, as biomarkers for non-small cell lung cancer (NSCLC) 
clinical outcome. We assessed seven pre-treatment serum laboratory test levels vi  
in 2,675 NSCLC patients, including 623 early stage and 2,052 advanced stage 
patients. Among 978 advanced stage NSCLC patients we studied who were 
treated with platinum-based chemotherapy, lower than normal levels of albumin, 
higher than normal levels of alkaline phosphatase and lactate dehydrogenase 
were all associated with worse 2-year overall survival, after adjusting for other 
variables. In addition, there was a cumulative effect among these three adverse 
laboratory test levels. 
In conclusion, low serum bilirubin levels are associated with higher risks of 
lung cancer incidence and mortality in male smokers and may be used to identify 
higher risk smokers for lung cancer. In addition, pre-treatment laboratory test 
levels indicative of metabolic status could be utilized to enhance predictions of 
survival among advanced stage NSCLC patients treated with platinum-based 
chemotherapy. Taken together, our results suggested that metabolic alterations 
associated with lung cancer could serve as novel serum biomarkers with clinical 
significance for lung cancer early detection and clinical outcome. 
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Chapter 1. Introduction   
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 1.1. Lung Cancer Epidemiology 
1.1.1. Incidence and mortality 
Approximately 1.6 million lung cancer cases are newly diagnosed each 
year worldwide, accounting for about 13% of all cancer cases (1). Lung cancer is 
the most common cancer in males and the fourth most commonly diagnosed 
cancer in females worldwide (1). In the United States, approximately 224,210 
cases of lung cancer are expected to be newly diagnosed in 2014 (2). It’s the 
second most common cancer in both males and females, accounting for about 13% 
of all cancer cases diagnosed. In the US, the incident rates of lung cancer have 
been declining since the mid-1980s in males, and have just started declining in 
females since the mid-2000s. From 2006 to 2010, incidence rates decreased by 
1.9% per year in males and by 1.2% per year in females (2). The median age at 
diagnosis is approximately 70 years (3). Lung cancer incidence rates are different 
among ethnic groups. In the US, incidence rates are highest among black males, 
which is 40% higher than in white males. 
Worldwide, lung cancer accounts for nearly 1.4 million deaths each year – 
18% of overall cancer-related mortality (3). It is the leading cause of 
cancer-related mortality in males, and the second leading cause of cancer-related 
mortality in females worldwide (1). In the US, approximately 159,260 patients are 
expected to die from lung cancer in 2014. It’s the leading cause of cancer-related 
mortality in both males and females, accounting for about 27% of all 2  
cancer-related mortality in the US, more than the mortality attributed to the next 
four most deadly cancers combined (breast, prostate, colon and pancreatic 
cancers) (2). Mortality rates started declining in the early 1990s in males, and 
mid-2000s in females. From 2006 to 2010, mortality rates decreased by 2.9% per 
year in males and by 1.4% per year in females. On the other hand, lung cancer 
incidence and mortality rates are still on the rise in many other countries (3). 
Worldwide, the highest lung cancer incidence rates in males are observed 
in Central and Eastern Europe, Northern America, while the lowest rates are 
observed in sub-Saharan Africa. In females, the highest lung cancer incidence 
rates are observed in Northern America and Northern Europe, and the lowest 
rates are observed in Africa as well (1). 
1.1.2. Risk factors 
Tobacco smoking has been recognized as the most predominant risk factor 
for lung cancer since the 1950s. Tobacco smoking is estimated to account for 80% 
of the worldwide lung cancer burden among males and over 50% of the burden in 
females (1). However, less than 10% of ever-smokers develop lung cancer. Both 
smoking intensity (i.e. number of cigarettes smoked per day) and duration of 
smoking increase lung cancer risks. Other factors of smoking influencing lung 
cancer risk include age starting to smoke, time since quitting and types of tobacco 
products smoked. Lung cancer risks are at least ten-times higher among smokers 
compared to those who never smoked, in both males and females (4). Former 
smokers have a lower risk of lung cancer, although risk is still higher among 
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former smokers compared to never-smokers. The observed differences in lung 
cancer incidence rates across countries and between genders are primarily due to 
differences in the smoking epidemic (1). Besides cigarettes, cigar or pipe smoking 
also increases lung cancer risk. 
Exposure to second-hand smoking is a major risk factor for those who do 
not smoke. It is estimated that 40% of non-smokers in the US are exposed to 
second-hand smoking, which increases lung cancer risk by up to 30% and 
contributes to around 3,000 lung cancer deaths each year. 
Exposure to radon gas, which is commonly released from construction 
materials, is responsible for over 20,000 lung cancer cases each year in the 
United States, making it the second leading risk factor for lung cancer in North 
America and Europe (2). Other known risk factors include environmental or 
occupational exposure asbestos, air pollution, diesel exhaust, radiation, polycyclic 
aromatic hydrocarbons (PAHs) as well as certain metals (arsenic, chromium and 
cadmium). There is also interaction among these risk factors, e.g. asbestos 
exposure and cigarette smoking have been shown to jointly increase lung cancer 
risk (5).  
Of note, although smoking is less prevalent in Chinese females (less than 
4% adults) compared to those in certain European countries such as Germany 
and Italy (about 20% adults), lung cancer incidence rates are higher among 
Chinese females, presumably reflecting indoor air pollution from stoves fueled by 
coal and without ventilation and from cooking fumes in China (1). Other risk 
factors include a family or personal history of cancer as well as a medical history 4  
of tuberculosis. Genetics also plays a contributing role in lung cancer 
carcinogenesis, particularly among patients with early age-onset (3). 
1.2. Lung Cancer Treatment and Survival 
Lung cancer can be broadly categorized into two major histopathologic 
groups: small-cell lung cancer (SCLC, 14% of cases) and non-small cell lung 
cancer (NSCLC, 84% of cases) for the purposes of treatment (6). NSCLCs are of 
epithelial cells origin, while SCLCs are of endocrine cells origin. NSCLC can be 
further classified into several subtypes based on different characteristics of tumor 
cells, which includes adenocarcinoma (~40%), squamous cell carcinoma (25% - 
30%), large cell carcinoma (10% - 15%) as well as bronchioloalveolar carcinoma 
(3).  
Treatment regimens include surgery, radiation therapy, chemotherapy and 
targeted therapy, depending on type and stage of disease, as well as molecular 
characteristics of the tumors (6). For SCLC, radiation therapy alone is the 
standard treatment for limited disease (LD), while radiation therapy in combination 
with chemotherapy is the standard treatment for extensive disease (ED) (6). A 
majority of patients experience at least temporary remission under this regimen, 
although they often experience recurrence later.  
For NSCLC patients with localized diseases, surgery is usually the 
treatment of choice. Survival is improved when chemotherapy is administered 
after surgery for most of these patients. About 30% of early stage patients will 
develop recurrence or progress to metastatic disease. Therefore, besides overall 
5  
survival, prevention of recurrence and progression is another major concern for 
early stage NSCLC patients. For advanced stage NSCLC patients, chemotherapy, 
radiation therapy or a combination of both are used for treatment (6) (Figure 1). 
Currently, the standard treatment for advanced stage NSCLC patients is 
platinum-based chemotherapy, with an overall response rate of 17% to 32% and a 
moderately improved survival among patients. Radiation therapy is usually 
administered either concurrently or sequentially in combination with 
chemotherapy. However, many patients develop severe toxic effects from the 
treatment. Therefore, patients with advanced stage NSCLC are often treated with 
palliative purposes to reduce symptoms and to improve quality of life. Targeted 
therapies are used to treat advanced stage NSCLC as well (3).  
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Figure 1. Non-Small Cell Lung Cancer Treatment Patterns by Stage, 2008. 
 
Chemo indicates chemotherapy (may include common targeted therapies); RT, 
radiation therapy. Percentages do not sum to 100% due to rounding. Data source: 
NCDB (6). Reprinted by permission from CA CANCER J CLIN, copyright (2012). 
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Overall outcomes for all stages of lung cancer have improved in recent 
years. The 1-year survival rate has increased during the past several decades 
primarily due to improvements in surgical techniques and chemotherapy for lung 
cancer. However, the overall 5-year survival rate for lung cancer has remained 
relatively unchanged at approximately 15% for the past two decades (2). The 
5-year survival rates for local, regional and distant diseases are 54%, 26% and 4% 
(Figure 2), respectively. Therefore, early detection is the best way to reduce lung 
cancer mortality. However, only 15% of lung cancer cases are diagnosed at the 
local stage. Most lung cancer patients are diagnosed at inoperable advanced 
stages when the prognosis is particularly dismal, as the early stage disease is 
typically asymptomatic (3). The overall 5-year survival rate is 6% for SCLC and 18% 
for NSCLC (6). Among NSCLCs, patients with adenocarcinoma usually have 
better prognosis compared to those with other subtypes, while patients with large 
cell carcinoma usually have worse prognosis since tumors are often poorly 
differentiated and metastasize early. 
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Figure 2. Five-Year Relative Survival Rates (A) and Stage Distribution (B) of 
Lung Cancer by Race and Stage at Diagnosis. 
United States, 2003 to 2009 (2). Reprinted by permission from CA CANCER J 
CLIN copyright (2014). 
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1.3. Lung Cancer Prognostic and Predictive Factors 
Survival time varies significantly among lung cancer patients, with some 
patients surviving years, and others less than a few months. Besides the 
well-known TNM stage, several other factors have been shown to affect clinical 
outcomes among NSCLC patients. These factors can be classified as prognostic 
or predictive markers. A prognostic factor is a characteristic that indicates the 
course of disease and clinical outcomes irrespective of treatments – it indicates 
the effect of the tumor on the patient. A predictive marker is a characteristic that 
indicates better clinical outcomes from a specific treatment, which determines the 
effect of treatment on the tumor (7, 8). Prognostic factors may help identify 
patients who are more likely to experience recurrence or progression to advanced 
disease and facilitate physicians making treatment plans accordingly, while 
predictive factors could be used to predict treatment responses, thus maximizing 
responses from effective treatments, minimizing toxicity associated with 
ineffective cytotoxic treatments and therefore improve overall survival and quality 
of life with personalized treatments. Several variables have been identified as 
prognostic/predictive markers for NSCLC clinical outcomes as our understanding 
in the molecular mechanisms underlying NSCLC tumorigenesis evolves (8). 
Prognostic factors for NSCLC can generally be grouped into three 
categories: patient-related factors (e.g. age, gender, performance status and 
comorbidity, etc.), tumor-related factors (e.g. TNM stage, tumor histology and 
grade, etc.) and environmental factors (e.g. nutritional status, etc.). Several 
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molecular markers have been well studied as prognostic factors for NSCLC, e.g., 
excision repair cross-complementation group 1 protein (ERCC1), P53, KRAS and 
EGFR (7). Several studies have also investigated clinical and laboratory variables 
as prognostic factors for lung cancer clinical outcomes, and to guide selection of 
treatment plan. Among those, only a few are validated and used clinically as 
prognostic factors, e.g. TNM stage and performance status of patients. The 
clinical utility of other factors, e.g. clinical laboratory tests, although suggested by 
some studies, are still controversial and requires further large studies, preferably 
in large randomized clinical trials (RCTs) (9). 
1.4. Lung Cancer Screening 
In 2011, the National Lung Screening Trial (NLST) concluded that low-dose 
helical computed tomography (LDCT) screening of high-risk individuals could 
reduce lung cancer mortality by 20% among current and former heavy smokers 
compared with standard chest x-ray based on findings from 53,454 participants 
enrolled (10). Based on these findings, LDCT screening according to NLST 
selection criteria, i.e., current or former smokers aged 55-74 years with at least 30 
pack-years of smoking history and no more than 15 years since quitting, has been 
recommended by the majority of professional organizations in the US (11-14). 
Moreover, it has recently been reported that participants with the highest risk for 
lung cancer deaths accounted for the most screening-prevented lung-cancer 
deaths and benefitted most from LDCT, while very few deaths were prevented 
among those at lowest risk (15). However, the feasibility of large-scale screening 
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is limited by a false positive rate of greater than 95% (10, 11). Biomarkers are 
urgently needed for improving risk prediction for lung cancer beyond smoking 
variables alone to reduce false positives and shift the balance towards higher 
cost-effectiveness for screening and early detection of lung cancer. 
1.5. Cancer Biomarkers 
According to the definition of National Cancer Institute, a biomarker is “a 
biological molecule found in blood, other body fluids or in tissues that is a sign of a 
normal or abnormal process, or of a condition or disease” (16). Accordingly, 
sources of biomarkers include whole blood/plasma/serum, urine, sputum, tissue 
or peripheral blood lymphocyte, etc. Cancer biomarkers can be used to assess 
exposure or disease risk, screen the general population, aid in the diagnosis and 
clinical staging of cancer, predict response or resistance to a specific treatment, 
monitor disease course to assess recurrence or progression, or serve as 
prognostic factors for disease, etc. (16). Cancer biomarkers can be applied across 
the cancer continuum, offering one of the best ways for risk prediction, early 
diagnosis, therapeutic response prediction and prognosis.  
1.5.1. Classification of biomarkers 
Generally, cancer biomarkers can be produced from either the tumor itself 
or other tissues in response to the presence of tumor or other conditions 
associated with the tumor. There are four categories of cancer molecular 
biomarkers: (i) risk biomarkers, which are factors associated with or contributing 
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to the carcinogenesis process, examples of which include genetic risk factors, 
high estradiol levels for breast cancer patients as well as HPV infection for 
cervical cancer patients; (ii) released biomarkers, which are factors released in 
abnormal levels in cancer patients due to anatomical or metabolic abnormality 
associated with tumor, examples of which include high PSA levels in prostate 
cancer patients or blood in stools in colorectal cancer patients; (iii) response 
biomarkers, e.g. antibodies and acute-phase reactants (17), which are factors 
generated by the body in response to the tumor; (iv) carcinogenesis biomarkers, 
such as DNA mutation or hyper-methylation, which are shed by the tumor and 
products of the carcinogenic process (18). 
There are potential limitations associated with each class of biomarkers. 
Risk biomarkers could be used to predict individual’s cancer risk. However, for a 
given risk biomarker, only a small percentage of individuals with the risk factor 
would develop cancer. Therefore, the integration of several risk biomarkers into a 
risk prediction model is necessary to improve the prediction. Release biomarkers 
are present in abnormal levels in cancer patients due to the presence of the tumor. 
However, other conditions could also lead to abnormal levels of these factors 
since they are often non-specific molecular biomarkers for cancer. Similarly, many 
other pathological conditions could lead to generation of response biomarkers by 
the body. Conversely, carcinogenesis biomarkers are a group of markers that are 
specific for patients with different types of cancer. Depending on the purpose and 
design of the study, carcinogenesis biomarkers may be identified for early 
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diagnosis of cancer, although they are more likely to be present in metastatic or 
invasive tumors.  
1.5.2. Blood-based biomarkers 
Blood/serum/plasma is the most common source for biomarker studies and 
the most used biological material in the clinic. It offers several advantages over 
other biological samples: (i) it is minimally invasive to obtain blood samples; (ii) it’s 
abundant and could be obtained serially to allow for disease follow-up; (iii) blood 
serves as a metabolic source/sink and reflects the cumulative impact of all organ 
systems including perturbations relating to disease. However, one of the major 
disadvantages with blood for biomarker studies is that analytes in blood, including 
RNAs, proteins and metabolites, usually present at levels spanning a large range, 
making it difficult to measure all analytes accurately (19). Nevertheless, 
blood/serum/plasma is still the most cost-effective and widely used source for 
biomarker studies. Unfortunately, there are not many validated serum biomarkers 
of sufficient sensitivity and specificity that can be applied clinically.  
1.5.3. Tumor-derived biomarkers 
Tissue is another important source for cancer biomarker studies. 
Tissue-based biomarkers from the tumor are more specific to the underlying 
cancer and reflect more directly the pathogenic process compared to biomarkers 
from other sources. However, the sampling procedure is usually invasive, and 
therefore more difficult and costly to obtain. Moreover, tumor samples are usually 
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obtained at a single time point (at the time of surgery) and are less amenable for 
tracking disease status or progression.  
Biomarkers with clinical significance can be applied along the cancer 
continuum to substantially reduce cancer burden through risk prediction, 
prevention, early detection, personalized treatment and disease monitoring after 
treatment. During the past decade, there have been substantial new discoveries 
on cancer biomarkers with the application of large-scale high-throughput 
technologies. However, thus far, very few biomarkers have been validated and 
applied in the clinic. One major problem is the lack of validation for the identified 
biomarkers. Many studies lacked a replication phase, and few biomarkers have 
been prospectively validated, which minimizes biases and reverse causality. 
Another major concern is the relatively low sensitivity or specificity of the 
candidate biomarkers. Many potential biomarkers don’t have sufficient sensitivity 
and specificity to be useful in the clinic for decision-making purposes. 
Nevertheless, those markers that are not specific to cancer could serve as 
markers of other diseases and pathologies that are associated with cancer, 
including inflammation, anemia, malnutritrion, cachexia, etc.  
1.6. Cancer Metabolism  
It is well established that cancer cells undergo profound changes in cellular 
metabolism to sustain the additional demands for energy and synthesis of 
essential biochemical precursors required for uncontrolled proliferation (20). 
Metabolic reprogramming has been increasingly recognized as an emerging 
15  
hallmark of cancer, providing cancer cells with energy and biosynthetic materials 
to support continuous cell growth and proliferation in cancer (21). Alterations in 
several pathways, including glycolysis, glutaminolyis and mitochondrial 
biogenesis are among the most significant alterations of cancer cell metabolism, 
supporting both cancer initiation and progression. They provide cancer cells both 
the energy required as well as metabolites for synthesizing macromolecules and 
organelles for cell proliferation. For example, increased glycolysis in cancer cells 
diverts glycolytic intermediates to molecules used for generating nucleosides and 
amino acids, which facilitates macromolecules biosynthesis (22). Therefore, a 
deep understanding of the fundamental metabolic changes that occur during lung 
cancer development could lead to the identification of novel biomarkers for lung 
cancer early diagnosis. 
1.7. Metabolomics  
Metabolomics is the systematic, unbiased study of the unique chemical 
fingerprints generated by metabolic processes that can inform the cellular 
processes of an organism (23). In the first issue of the new decade, Nature asked 
a selection of leading researchers and policy-makers in five areas where their 
fields would be ten years from then, and one of the fields chosen was 
metabolomics (23). In contrast to the widely studied genomics and 
transcriptomics, metabolomics is an emerging science. Metabolites include the 
end products of the cellular processes, which represent the distal read-out of the 
cellular state. It is therefore thought that metabolomic profiling reflects 
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physiological functions and pathological characteristics in greatest detail. As part 
of a system biology perspective, metabolomic profiling has become an important 
complement to the other “omic” approaches including genomics, epigenomics, 
transcriptomics, and proteomics and is emerging as an important tool to identify 
biomarkers for the early detection, diagnosis, and prognosis of cancers (24).  
Multiple technologies have been applied for metabolomic profiling, 
including nuclear magnetic resonance (NMR), high pressure liquid 
chromatography (HPLC), gas chromatography/mass spectrometry and liquid 
chromatography/mass spectrometry (GC/MS and LC/MS). Among these, NMR 
has the limitation of defining only named compounds, although it is sensitive and 
high-throughput. HPLC requires an external standard and identifies compounds 
based solely on their chromatographic retention time. On the other hand, GC/MS 
and LC/MS are sensitive and allow for both identification of known metabolites 
and characterization of unknown compounds (24).  
Several studies have utilized metabolomic profiling to reveal metabolic 
alterations associated with various malignancies, including breast (25), colorectal 
(26), esophageal (27), gastric (28), liver (29), kidney (30), oral (31), pancreatic (32) 
and prostate (24) cancers. Recently, a few studies have investigated metabolic 
profiles of lung cancer patients (33-35). However, they only targeted and 
measured a small, selected number of metabolites.  
1.8. Hypothesis and Rationale 
1.8.1. Hypothesis I: Global metabolomic profiling could identify serum metabolites 17  
that are differentially expressed during lung cancer development, which 
could consequently be used as novel biomarkers for the early detection of 
lung cancer. 
Cancer cells have been known to acquire altered cellular metabolism to 
sustain the additional demands for energy and other biochemical precursors for 
uncontrolled proliferation. Metabolomic profiling offers a functional readout of the 
physiological state and a comprehensive picture of the metabolic changes 
associated with cancer development. We therefore hypothesized that global 
metabolomics profiling followed by target validation of individual metabolites can 
identify serum metabolites as potential biomarkers for the early detection of lung 
cancer. In this study, we propose to use a global metabolomic profiling platform, 
which can measure hundreds of metabolites simultaneously, to provide a 
comprehensive assessment of metabolites from serum of NSCLC patients 
compared to paired healthy control subjects. These metabolomic profiles can 
guide the identification of novel biomarkers for early detection of NSCLC. 
1.8.2. Hypothesis II: Pre-treatment clinical laboratory tests indicative of metabolic 
status are associated with survival in NSCLC patients, which could serve 
as biomarkers for clinical outcome in NSCLC patients. 
Survival time varies significantly among early stage or late stage NSCLC 
patients. Clinically relevant biomarkers that predict prognosis and survival time 
are urgently needed to personalize treatment regimens and manage expectations. 
Patients’ pre-treatment clinical laboratory test levels are reflective of 18  
patient-related and environmental factors. Serum pre-treatment laboratory test 
levels have long been reported to be prognostic factors for SCLC (36). Therefore, 
we hypothesized that pre-treatment laboratory test levels that indicate metabolic 
status are associated with NSCLC patients’ survival, and could be utilized as 
biomarkers for NSCLC clinical outcome prediction. 
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2.1. Study Population and Data Collection 
MD Anderson Case-Control Population in Metabolomics Study 
The lung cancer cases and control subjects were from an ongoing lung 
cancer case-control study at the University of Texas MD Anderson Cancer Center 
(37). Cases were newly diagnosed, histologically confirmed non-small cell lung 
cancer (NSCLC) patients previously untreated with chemotherapy or radiotherapy 
at MD Anderson Cancer Center. There were no restrictions on age, sex, or 
ethnicity at study recruitment. Early stage NSCLC included stages I and II, while 
late stage NSCLC included stages III and IV. The controls were recruited in the 
Kelsey Seybold Clinics, Houston’s largest private multispecialty group practice 
with 18 clinics in the Houston metropolitan area. The control subjects were 
healthy individuals without prior history of cancer (except for non-melanoma skin 
cancer). To control for the confounding effect of ethnicity, we only included 
Caucasians in this study. Twenty each of controls, early-stage, and late-stage 
NSCLC cases (hereafter referred to as “trio”) were used for metabolomic profiling. 
Promising metabolites identified from this profiling were examined in two 
additional case-control samples, consisting of 50 trios and 123 trios, respectively 
(Figure 3). All participants completed an in-person interview administered by MD 
Anderson staff interviewers using a structured questionnaire. Demographic 
characteristics, smoking history, family history of cancer, environmental 
exposures and other epidemiologic data were collected and recorded. At the end 
of the interview, each participant donated 40ml blood sample for molecular 
analysis. 
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All patients and controls gave written informed consent before participation, 
and the study was approved by the Institutional Review Boards of the MD 
Anderson Cancer Center and the Kelsey Seybold Clinics. 
The Taiwanese Prospective Cohort Population for Metabolomic Validation 
The Taiwanese prospective cohort population was obtained from a 
standard medical screening program conducted by the MJ Health Management 
Institution at Taiwan (hereon referred to as “MJ”). From 1994 to 2008, a total of 
435,985 subjects aged 20 years and older, free of cancer at baseline, were 
recruited. Median follow-up time for the cohort is 8 years (interquartile range: 5-11 
years) for male participants and 9 years (interquartile range: 5-11 years) for 
female participants. All participants completed a self-administered questionnaire 
covering demographic characteristics and health history. All subjects underwent a 
series of medical tests for blood, urine, physical examination, body 
measurements and functional tests, including testing for anthropometric 
measurements (e.g., height, weight, waist circumference, hip circumference, body 
fat percentage, etc.), blood pressure, pulse rate and respiration rate. Overnight 
fasting blood was analyzed for a standard panel, including hemogram and testing 
for blood sugar, liver function, renal function, thyroid function, blood lipids and 
blood grouping. The cohort members were followed through 2008 for cancer and 
vital status, which were assessed by linkage of the individual ID to the National 
Cancer Registry and National Death file.  
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All participants signed an informed consent. The studies were approved by 
the Institutional Review Boards of the University of Texas MD Anderson Cancer 
Center and National Health Research Institutes, Taiwan. 
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Figure 3. Study design of lung cancer metabolomic profiling and validation 
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MD Anderson Lung Cancer Patient Population for Lung Cancer Clinical Outcome 
This study was conducted in 2,806 patients with newly diagnosed, 
histologically confirmed NSCLC recruited at the University of Texas MD Anderson 
Cancer Center. None of the study subjects had undergone chemotherapy or 
radiotherapy treatment before study enrollment. There were no restrictions on age, 
sex, or ethnicity at recruitment. Excluding 131 patients with unknown clinical stage 
information, there were 2,675 patients remaining for analysis. Early stage NSCLC 
included stages I and II patients, while advanced stage NSCLC included stages III 
and IV patients. All participants completed an in-person interview by trained MD 
Anderson Cancer Center staff using a structured questionnaire. Demographic 
characteristics, smoking history, family history of cancer, and exposure data were 
collected. After the interview, each participant donated 40 ml blood sample for 
molecular analysis. Clinical and follow-up data were extracted from medical 
charts by trained medical staff. Pretreatment serum levels of albumin, alkaline 
phosphatase, alanine aminotransferase, total bilirubin, glucose, lactate 
dehydrogenase and total protein were measured as part of a standard battery of 
tests evaluating patients’ overall metabolic status. The normal ranges of the tests 
were based on standard laboratory norms. All study subjects had their blood 
drawn and laboratory tests evaluated no earlier than 30 days before diagnosis 
and before implementation of any treatment. 
All patients signed written informed consent before participation, and the 
study was approved by the Institutional Review Board of the University of Texas 
MD Anderson Cancer Center. 
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2.2. Global Metabolomic Profiling 
The metabolomic profiling analysis of all samples was carried out by 
Metabolon, Inc (Durham, NC) using the following general protocol described 
previously (38). Briefly, this process involved: sample extraction, separation, 
detection, spectral analysis, data normalization, delineation of class-specific 
metabolites and pathway mapping. All samples were randomized prior to mass 
spectrometric analyses to avoid any experimental drifts. A number of internal 
standards, including injection standards, process standards, and alignment 
standards were used to assure QA/QC targets were met and to control for 
experimental variability. Samples were kept frozen until assays were ready to be 
performed. The samples were extracted and divided into three equal portions for 
analysis on one of the three platforms: ultrahigh performance liquid 
chromatography/tandem mass spectrometry (UHLC/MS/MS2) optimized for basic 
species, UHLC/MS/MS2 optimized for acidic species, and gas 
chromatography/mass spectrometry (GC/MS). For UHLC/MS/MS2 analysis, two 
aliquots were processed with one using acidic positive ion optimized conditions 
and the other using basic negative ion optimized conditions in two independent 
injections using separate dedicated columns. The platform includes a Waters 
ACQUITY ultra-performance liquid chromatography (UPLC) system (Waters, 
Millford, MA) and an LTQ mass spectrometer (Thermo Fisher Scientific, Inc., 
Waltham, MA) comprised of electrospray ionization (ESI) source and linear 
ion-trap (LIT) mass analyzer. The MS instrument scans 99-1000 m/z and 
alternates between MS and MS2 scans using dynamic exclusion with 
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approximately 6 scans per second. For GC/MS analysis, one aliquot was used 
and separated on a 5% phenyldimethyl silicone column with helium as the carrier 
gas and a temperature ramp from 60°C to 340°C. The platform includes a 
Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer 
that uses electron impact ionization (Thermo Fisher Scientific, Inc.) and has a 
50-750 atomic mass unit scan range. Metabolites were identified by automated 
comparison of the ion features in the experimental samples to the metabolomic 
library of chemical standard entries using software developed at Metabolon (39). 
Known chemical entities were mapped to the metabolomic library entries of 
purified standards. Identification of additional entities was based on the virtue of 
their recurrent nature (both chromatographic and mass spectral). 
2.3. Quantification of individual metabolites 
Gamma-glutamylalanine and bilirubin standard powders were purchased 
from Sigma-Aldrich (St. Louis, MO). Individual metabolite quantification was done 
at Texas Southern University (Houston, TX). Quantification of individual 
metabolite in serum was determined by LC-MS/MS methods using a 3200 
QTRAP® MS/MS coupled by an Agilent 1200 Series HPLC system. Standard 
curves for each compound were constructed by spiking known amount of the 
standard to a series of blank plasma (Gulf Coast Blood Bank, Houston, TX). For 
the determination of λ-glutamylalanine, aliquot of serum samples (50 µL) was 
mixed with 500 µL of a 2:1 ratio (v/v) solution of methanol/acetone containing 
etravirine as an internal standard. After a brief vortex and centrifugation, the 
supernatant was transferred to a 12x75 mm glass tube where it was dried under 
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pure nitrogen. The residual was then reconstituted with 100 µL of a 1:1 (v/v) 
solution of methanol/water before HPLC injection. Gamma-glutamylalanine and 
the internal standard were separated on a reverse phase XTerra MS-C18 (2.1 x 
50mm, 3.5 μm) column. The mobile phases consisted of a 0.5 mM ammonium 
acetate aqueous solution (mobile phase A) and a 100% acetonitrile solution 
(mobile phase B). A gradient elution starting with 95% mobile phase A at a flow 
rate of 200 µL/min was applied to achieve retention time of 0.69 min and 4.3 min 
for λ-glutamylalanine and the internal standard, respectively. For the 
determination of bilirubin, aliquot of serum samples (50 µL) was mixed with 250 
µL of methanol containing etravirine as an internal standard. After a brief vortex 
and centrifugation, the supernatant was injected directly onto the HPLC system. 
Bilirubin and the internal standard were separated on a reverse phase XTerra 
MS-C18 (2.1 x 50mm, 3.5 μm) column. The mobile phases consisted of a 2 mM 
ammonium acetate aqueous solution adjusted to pH 7.8 by ammonium hydroxide 
(mobile phase A) and a 98% methanol solution containing 2% (v/v) of a 2 mM 
ammonium acetate (mobile phase B). A gradient elution starting with 70% mobile 
phase A at a flow rate of 200 µL/min was applied to achieve retention time of 5.6 
min and 5.8 min for bilirubin and the internal standard, respectively.    
Mass spectrometric detection was performed on a 3200 QTRAP® (AB 
Sciex, Foster City, CA, USA), a hybrid triple quadrupole linear ion trap equipped 
with a TurboIonspray ion source. A Parker Balston Source 5000Tri Gas generator 
was used to generate pure nitrogen. The mass spectrophotometer was set at the 
negative mode. The transition ions were detected using multiple reaction 
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monitoring from a specific parent ion transition to product ion for λ-glutamylalanine 
(m/z 217128), bilirubin (583.4285), and etravirine (432.9141.6). Peak areas 
and other compound parameters were determined by Analyst R software, version 
1.5. Standard curve ranges are 25 – 500 ng/mL and 500 – 10,000 ng/mL for 
λ-glutamylalanine and bilirubin, respectively. 
2.4. Statistical Analyses 
Lung Cancer Metabolomic Profiling Study 
In the case-control analysis, the Pearson χ2 test was used to examine the 
differences in sex and smoking status between cases and controls. Student’s t 
test was used to test for differences in age and pack-years of smoking as 
continuous variables. For the metabolomic profiling assay, missing metabolite 
measurements, which were due to levels below detection limits, were imputed 
with the compound minimum (minimum value imputation). Only metabolites with 
detectable expression in at least 80% of the samples were analyzed. 
Nonparametric two-sided Wilcoxon rank-sum tests were used to analyze the 
differences of metabolite levels between cases and controls for both metabolomic 
profiling and individual metabolite validation assay. Nonparametric trend test was 
used to analyze the trend across normal controls, early stage lung cancer and late 
stage lung cancer cases for both metabolomic profiling and individual metabolite 
validation assay. Spearman’s correlation test was used to assess the correlation 
between the two values measured with metabolomic profiling and individual 
metabolite assay with LC-MS/MS.  
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For the MJ cohort, serum total bilirubin levels were divided into three 
groups with equal tertile in men or women. Cox proportional hazard models were 
used to assess the association of serum total bilirubin levels with lung cancer 
incidence or mortality rate using the highest tertile category of bilirubin levels (>1 
mg/dL for men and >0.82 mg/dL for women) as reference. For lung cancer 
incidence, the event time was from the date of recruitment to the end of follow-up, 
or the date of lung cancer identification if earlier. For lung cancer mortality, the 
event time was from the date of recruitment to the end of follow-up, or the date of 
death due to lung cancer if earlier. Hazard ratios were adjusted for age, 
educational level (middle school or lower, high school, junior college, or college or 
higher), body mass index (BMI) and pack-years of smoking in a multivariable 
model with continuous variables whenever appropriate. The proportional hazards 
assumption was assessed by plotting Schoenfeld residuals versus time and 
examining their correlation. Two-way interactions between smoking status and 
serum total bilirubin levels were assessed for lung cancer incidence and mortality 
in men and women. Non-parametric trend tests were used to analyze the trend of 
serum total bilirubin levels across each characteristic group of the cohort (e.g., 
age, BMI, etc). All statistical tests were two-sided with the threshold for 
significance set at 0.05. Statistical analyses were performed using STATA 10.0 
(StataCorp, College Station, TX).  
Clinical Laboratory Tests and Lung Cancer Clinical Outcome Study 
The primary endpoint for this study was overall survival. Secondary 
endpoints for early stage NSCLC patients were recurrence and progression. 
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Survival time was calculated from the date of diagnosis to the date of death or last 
patient follow-up. Chi-square test was used to assess differences in patient 
characteristics. Multivariable Cox proportional hazards model was used to assess 
the effect of each pretreatment serum laboratory test level on 2-year or 5-year 
survival, adjusted for age, sex, smoking status, clinical stage, and treatment 
regimen. Kaplan-Meier survival analysis was used to estimate survival, and 
log-rank tests were used to assess the differences in overall survival for each 
laboratory test. The cumulative effects of multiple unfavorable laboratory test 
levels were evaluated for the three tests that showed statistical significance in the 
main analysis (i.e., P < 0.05). The lab-test based risk score for each patient was 
derived by linear combination of the product of reference-normalized expression 
level of each laboratory test by its Cox regression corresponding coefficient (21). 
All patients were dichotomized by the median risk score, and individuals with a 
risk score higher or lower than the median were classified as high or low risk 
groups, respectively. A P value less than 0.05 was considered significant in all 
statistical analyses. All statistical analyses were conducted using STATA software, 
version 10 (StataCorp, College Station). 
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3.1. Lung Cancer Metabolomic Profiling Study 
3.1.1. Characteristics of the study population 
In the case-control studies, the lung cancer cases and healthy controls 
were all Caucasians, matched on age and gender (Table 1). The Taiwanese MJ 
cohort consisted of 425,660 subjects (202,902 men and 222,758 women) aged 20 
years and older (Table 2). Median follow-up time for this cohort was 8 years 
(interquartile range [IQR], 5-11 years) for men and 9 years (IQR, 5-11 years) for 
women, which yielded a total of more than 3.4 million person-years of follow-up. 
The average age at testing was 41 for both men and women. Median total 
bilirubin level was 0.87 mg/dL (IQR, 0.68-1.11 mg/dL) in men and 0.7 mg/dL (IQR, 
0.56-0.9 mg/dL) in women. Serum total bilirubin levels were higher in men than in 
women, which were consistent with previous studies (40, 41). Selected 
demographic characteristics and exposures of the cohort participants are shown 
in Table 2, presented by gender and tertiles of bilirubin level (<0.75, 0.75-1 and >1 
mg/dL for men and <0.61, 0.61-0.82 and >0.82 mg/dL for women). Distribution of 
serum total bilirubin levels among the participants in the cohort is shown in Figure 
3. Among male participants in the cohort, over half (52.1%) were smokers, with 25% 
of them being heavy smokers of ≥30 pack-years. In contrast, only 17,123 (8.3%) 
female participants were smokers, with 1,327 (8.3%) of them being heavy 
smokers. During the follow-up, there were 809 incident lung cancer cases and 
614 lung cancer deaths among the males, and 524 lung cancer cases and 330 
deaths among the females. 
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Table 1. Selected host characteristics of three case-control populations 
 
Characteristics Phase I (N=60)   Phase II (N=150)   Phase III (N=369) 
  
Cases  
(N=40) 
Controls 
(N=20) 
P  
 
Cases  
(N=100) 
Controls  
(N=50) 
P  
 
Cases  
(N=246) 
Controls  
(N=123) 
P  
Age 
           
Mean (SD), y 62 (11) 59 (10) 0.38 
 
61 (12) 59 (12) 0.43 
 
64 (10) 64 (10) 0.82 
Sex, No. (%) 
           
Male 13 (32.5) 8 (40.0) 
  
40 (40.0) 20 (40.0) 
  
174 (70.7) 87 (70.7) 
 
Female 27 (67.5) 12 (60.0) 0.57 
 
60 (60.0) 30 (60.0) 1 
 
72 (29.3) 36 (29.3) 1 
Smoking status, No. (%) 
           
Non-smoker 6 (15.0) 7 (35.0) 
  
21 (21.0) 16 (32.0) 
  
37 (15.0) 34 (27.6) 
 
Smoker 34 (85.0) 13 (65.0) 0.19 
 
79 (79.0) 34 (68.0) 0.14 
 
209 (85.0) 89 (72.4) 0.009 
Pack year, Mean (SD) 48.0 (30.7) 54.1 (42.3) 0.59  44.7 (31.5) 48.5 (32.9) 0.57  52.1 (32.1) 33.9 (25.9) <0.001 
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Table 2. Characteristics of the participants in the prospective cohort by gender and serum total bilirubin levels a 
Characteristics Men (N = 202,902), N (%) 
 
Women (N = 222,758), N (%) 
 
Total 
 
Total bilirubin level (mg/dL) 
 
Total 
 
Total bilirubin level (mg/dL) 
  
  
>1 0.75-1 <0.75 
   
>0.82 0.61-0.82 <0.61 
Total 202,902 
 
67,841 (33.4) 65,540 (32.3) 69,521 (34.3) 
 
222,758 
 
75,189 (33.8) 72,207 (32.4) 75,362 (33.8) 
Age (y), mean (SD) 41 (14) 
 
40 (14) 42 (14) 41 (14) 
 
41 (14) 
 
41 (14) 42 (14) 41 (13) 
20-39 112,584 (55.5) 
 
39,399 (35.0) 35,270 (31.3) 37,915 (33.7) 
 
119,946 (53.9) 
 
41,854 (34.9) 37,510 (31.3) 40,582 (33.8) 
40-59 63,447 (31.3) 
 
19,927 (31.4) 21,201 (33.4) 22,319 (35.2) 
 
76,087 (34.2) 
 
23,908 (31.4) 25,500 (33.5) 26,679 (35.1) 
≥60 26,871 (13.2) 
 
8,515 (31.7) 9,069 (33.8) 9,287 (34.6) 
 
26,725 (12) 
 
9,427 (35.3) 9,197 (34.4) 8,101 (30.3) 
BMI (kg/m2), mean (SD) 23.9 (3.4) 
 
23.5 (3.3) 23.9 (3.3) 24.2 (3.4) 
 
22.3 (3.6) 
 
21.8 (3.5) 22.3 (3.6) 22.8 (3.7) 
<25 134,591 (66.4) 
 
47,499 (35.3) 43,264 (32.1) 43,828 (32.6) 
 
176,567 (79.3) 
 
62,056 (35.2) 57,139 (32.4) 57,372 (32.5) 
25-29.9 59,734 (29.5) 
 
18,062 (30.2) 19,565 (32.8) 22,107 (37.0) 
 
38,454 (17.3) 
 
11,040 (28.7) 12,660 (32.9) 14,754 (38.4) 
≥30 8,516 (4.2) 
 
2,264 (26.6) 2,696 (31.7) 3,556 (41.8) 
 
7,689 (3.5) 
 
2,080 (27.1) 2,394 (31.1) 3,215 (41.8) 
Educational levels 
           
Middle school or lower 40,499 (20.6) 
 
12,823 (31.7) 13,379 (33.0) 14,297 (35.3) 
 
70,385 (32.6) 
 
23,109 (32.8) 23,546 (33.5) 23,730 (33.7) 
High school 45,601 (23.2) 
 
14,665 (32.2) 14,693 (32.2) 16,243 (35.6) 
 
54,124 (25.1) 
 
17,238 (31.9) 17,186 (31.8) 19,700 (36.4) 
Junior college 45,367 (23.1) 
 
15,705 (34.6) 14,526 (32.0) 15,136 (33.4) 
 
42,941 (19.9) 
 
15,153 (35.3) 13,525 (31.5) 14,263 (33.2) 
College or higher 64,987 (33.1) 
 
22,603 (34.8) 20,844 (32.1) 21,540 (33.2) 
 
48,400 (22.4) 
 
17,428 (36.0) 15,692 (32.4) 15,280 (31.6) 
Smoking status 
           
Non-smoker 92,864 (47.9) 
 
35,175 (37.9) 30,188 (32.5) 27,501 (29.6) 
 
188,685 (91.7) 
 
64,488 (34.2) 61,534 (32.6) 62,663 (33.2) 
Smoker 101,092 (52.1) 
 
29,632 (29.3) 32,451 (32.1) 39,009 (38.6) 
 
17,123 (8.3) 
 
4,891 (28.6) 5,228 (30.5) 7,004 (40.9) 
<30 pack-years 72,153 (74.9) 
 
21,843 (30.3) 23,084 (32.0) 27,226 (37.7) 
 
14,662 (91.7) 
 
4,303 (29.4) 4,403 (30.0) 5,956 (40.6) 
≥30 pack-years 24,146 (25.1) 
 
6,269 (26.0) 7,777 (32.2) 10,100 (41.8) 
 
1,327 (8.3) 
 
279 (21) 434 (32.7) 614 (46.3) 
Lung cancer incidence 809 (0.4) 
 
215 (26.6) 270 (33.4) 324 (40.1) 
 
524 (0.2) 
 
155 (29.6) 187 (35.7) 182 (34.7) 
Lung cancer mortality 614 (0.3) 
 
147 (23.9) 214 (34.9) 253 (41.2) 
 
330 (0.2) 
 
107 (32.4) 115 (34.9) 108 (32.7) 
a Percentage may not total 100 because of rounding. 
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Figure 4. Distribution of serum total bilirubin levels among male (A) and 
female (B) participants in the MJ cohort.   
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3.1.2. Global metabolomic profiling of lung cancer 
Serum global metabolomic profiles of 40 lung cancer cases and 20 healthy 
controls (20 trios) were assessed in the initial case-control study and a total of 403 
named metabolites were identified. After exclusion of metabolites detected in less 
than 80% of samples, 306 (76%) metabolites remained. These metabolites were 
mapped to 8 super-pathways and 61 sub-pathways (Appendix B). Among these, 
24 metabolites exhibited significantly differential expression between lung cancer 
cases and healthy controls (Table 3). Furthermore, 29 metabolites exhibited a 
significant trend of expression when comparing normal controls, early and late 
stage cases, 12 of which had P for trend values < 0.01 (Table 4). 
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Table 3. Metabolites with significantly differential expression between lung 
cancer cases and healthy controls in metabolomic profiling. 
Metabolite 
Relative Expression Value 
 
Controls, Mean (SD)  
N=20 
Cases, Mean (SD)  
N=40 
P Value 
2-pyrrolidinone 184,592 (67,739) 120,309 (38,326) <0.001 
λ-glutamylalanine 73,251 (15,477) 55,538 (14,767) <0.001 
prolylhydroxyproline 99,837 (32,892) 147,019 (85,297) 0.003 
bradykinin, des-arg(9) 149,185 (191,016) 52,631 (57,472) 0.004 
citrate 4,436,480 (1,350,699) 3,526,780 (910,400) 0.008 
inosine 6,089 (7,742) 15,731 (25,092) 0.008 
octadecanedioate (C18) 18,830 (13,613) 25,914 (12,996) 0.009 
ascorbate (Vitamin C) 379,215 (354,715) 186,720 (262,879) 0.01 
xylonate 34,788 (19,194) 48,479 (21,691) 0.01 
ribose 65,583 (26,471) 92,345 (56,000) 0.02 
pyroglutamine* 83,523 (47,468) 120,072 (72,884) 0.02 
2-hydroxyglutarate 73,643 (22,606) 59,895 (21,528) 0.02 
bilirubin 42,818 (37,297) 28,382 (23,597) 0.03 
1-docosahexaenoyl-GPC* (22:6)* 326,254 (110,182) 460,063 (260,002) 0.03 
serotonin (5HT) 41,042 ( 26,983) 58,634 (33,030) 0.03 
alpha-tocopherol 1,275,449 (447,775) 16,23,417 (872,291) 0.03 
acetylcarnitine (C2) 1,127,480 (371,971) 1,292,182 (307,364) 0.03 
caproate (6:0) 55,317 ( 13,834) 49,014 (15,451) 0.03 
gamma-CEHC 9,740 (5,548) 6,694 (3,971) 0.04 
tryptophan 7,266,894 (1,210,393) 6,764,267 (1,438,869) 0.04 
nonadecanoate (19:0) 34,914 (20,482) 42,556 (19,167) 0.04 
citrulline 192,653 (61,750) 157,052 (45,065) 0.05 
3-hydroxybutyrate (BHBA) 3,537,910 (6,648,727) 5,629,617 (7,296,060) 0.05 
lathosterol 83,975 (37,169) 65,360 (37,853) 0.05 
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Table 4. Metabolites with significant trend of expression comparing normal 
controls, early stage and late stage cases in metabolomic profiling  
Metabolite 
Relative Expression Value 
 
Controls 
Mean (SD) 
N=20 
Early stage cases 
Mean (SD) 
N=20 
Late stage cases 
Mean (SD) 
N=20 
P Value 
λ-glutamylalanine 73,251 (15,477) 58,721 (15,063) 52,355 (14,121) <0.0001 
bradykinin,,des-arg(9) 149,185 (191,016) 72,002 (72,510) 33,260 (27,061) 0.0004 
2-pyrrolidinone 184,592 (67,739) 119,052 (40,019) 121,566 (37,554) 0.0007 
ribose 65,583 (26,471) 85,819 (74,815) 98,871 (27,388) 0.0008 
prolylhydroxyproline 99,837 (32,892) 145,811 (109,956) 148,228 (53,298) 0.001 
ascorbate (Vitamin,C) 379,215 (354,715) 241,922 (323,738) 131,519 (175,005) 0.003 
pyroglutamine 83,523 (47,468) 94,411 (38,913) 145,732 (89,461) 0.004 
bilirubin 42,818 (37,297) 34,885 (27,919) 21,879 (16,568) 0.005 
citrate 4,436,480 (1,350,699) 3,703,495 (826,483) 3,350,065 (975,942) 0.006 
dimethylglycine 374,999 (117,999) 394,627 (129,304) 519,430 (162,458) 0.007 
λ-glutamylglutamine 158,358 (41,747) 147,878 (48,266) 115,265 (50,958) 0.009 
allantoin 45,083 (18,638) 62,444 (60,083) 105,248 (75,072) 0.009 
xylonate 34,788 (19,194) 44,653 (14,651) 52,306 (26,838) 0.013 
citrulline 192,653 (61,750) 168,397 (36,799) 145,707 (50,432) 0.015 
taurochenodeoxycholate 35,192 (25,112) 36,905 (29,972) 107,807 (157,690) 0.015 
betaine 801,195 (206,034) 880,737 (261,529) 1,014,750 (243,831) 0.015 
octadecanedioate (C18) 18,830 (13,613) 24,281 (10,670) 27,548 (15,075) 0.019 
C-glycosyltryptophan* 30,314 (5,611) 31,348 (7,797) 42,725 (18,271) 0.021 
caproate (6:0) 55,317 (13,834) 51,113 (14,652) 46,915 (16,312) 0.023 
2-hydroxypalmitate 273,748 (54,880) 284,755 (59,536) 315,180 (67,137) 0.024 
N-acetylalanine 11,056 (1,936) 11,228 (1,837) 13,237 (3,363) 0.024 
N-acetylneuraminate 93,377 (30,573) 93,898 (46,055) 184,215 (142,088) 0.025 
beta-hydroxyisovalerate 23,341 (16,904) 20,560 (13,029) 32,634 (23,122) 0.027 
isoleucine 7,826,930 (1,625,275) 8,346,346 (2,541,086) 9,321,622 (2,069,754) 0.027 
2-ethylhexanoic,acid 837,760 (370,924) 808,623 (287,933) 622,298 (400,523) 0.027 
bilirubin (E,E)* 545,806 (488,517) 595,041 (394,994) 333,095 (247,461) 0.036 
benzoate 901,738 (163,812) 929,460 (118,775) 830,883 (136,694) 0.043 
taurolithocholate,3-sulfate 22,282 (14,217) 27,824 (26,186) 41,376 (28,524) 0.044 
glycocholate 74,886 (58,775) 81,622 (98,815) 144,855 (155,358) 0.048 
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3.1.3. Target validation of individual metabolites 
Metabolites exhibiting a significant trend in levels from normal individuals 
to early and late stage patients are potential biomarkers for the detection and 
prognosis of lung cancer. Of the 29 metabolites with significant trends, bilirubin 
caught our most interest given its potent endogenous cytoprotective properties 
and more importantly, its inverse association with cardiovascular disease and 
respiratory disease in previous reports (41-44). Therefore, we selected bilirubin 
and λ-glutamylalanine, which showed the most significant trend from metabolomic 
profiling for further validation. We developed standard LC/MS-MS assays for 
these metabolites and used these assays to measure their levels in the 20 trios of 
cases and controls from phase I of the case-control study; we found excellent 
correlation with metabolomic profiling data. We further examined levels of bilirubin 
and λ-glutamylalanine in additional 50 trios of serum samples (phase II) and 123 
trios of serum samples (phase III) from controls and early and late-stage patients 
(Table 5). Through this process, bilirubin emerged as a metabolite that 
consistently showed a statistically significant trend in all three sets of trio data. 
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Table 5. Levels of the two individual metabolites of interest measured with 
LC/MS-MS in the three case-control studies 
Metabolite Expression Level, Mean (SD) P Value 
 
Controls Early stage Late stage 
 
 
Phase I (N=60) 
 
 
(N = 20) (N = 20) (N = 20) 
 
λ-glutamylalanine (ng/mL) 98.28 (35.01) 68.06 (42.58) 73.96 (32.82) 0.03 
Bilirubin (μg/mL) 2.81 (1.43) 2.12 (1.29) 1.54 (0.84) 0.004 
 
Phase II (N=150) 
 
 
(N = 50) (N = 50) (N = 50) 
 
λ-glutamylalanine (ng/mL) 113.57 (43.01) 107.55 (42.68) 101.28 (36.3) 0.1 
Bilirubin (μg/mL) 3.10 (1.81) 2.78 (1.54) 1.91 (1.03) 0.0001 
 
Phase III (N=369) 
 
 
(N = 123) (N = 123) (N = 123) 
 
λ-glutamylalanine (ng/mL) 183.17 (81.69) 181.17 (104.05) 144.04 (78.6) 0.0002 
Bilirubin (μg/mL) 2.69 (1.77) 2.56 (1.73) 2.25 (1.47) 0.02    
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3.1.4. Validation of bilirubin as a lung cancer marker in a large cohort 
Since bilirubin is a routine blood test in health examination, we next 
assessed the association of blood test serum total bilirubin levels with lung cancer 
incidence and mortality using a large prospective cohort in Taiwan. In this cohort, 
younger age, lower BMI, never smoking status, lower systolic blood pressure and 
higher education status were all significantly associated with higher bilirubin levels 
in men (Supplementary Table 5). Similar associations were also observed in 
women. Total incidence rate for lung cancer was 5.64 (95 % CI, 5.26-6.05) per 
10,000 person-years in men and 3.17 (95 % CI, 2.90-3.46) in women. Total lung 
cancer specific mortality rate was 3.88 (95% CI, 3.58-4.20) per 10,000 
person-years in men and 1.85 (95% CI, 1.66-2.06) in women. Lower bilirubin level 
was associated with significantly higher rates of both lung cancer incidence and 
lung cancer specific mortality in men but not women. The incidence rate of lung 
cancer per 10,000 person-years in men was 4.27 (95% CI, 3.71-4.90) in the 
highest tertile of bilirubin level (>1 mg/dL) compared to 6.93 (95% CI, 6.20-7.75) 
in the lowest tertile (<0.75 mg/dL), which translated to a 52% increase in lung 
cancer incidence for the low bilirubin group (P < 0.001). The corresponding lung 
cancer specific mortality rate in men was 2.70 (95% CI, 2.30-3.17) in the highest 
tertile compared to 4.88 (95% CI, 4.32-5.52) in the lowest tertile, a 71% increase 
in lung cancer specific mortality for the low bilirubin group (P<0.001) (Table 10).  
As expected, there was a strong dose response relationship between lung 
cancer risk/mortality and pack-years of smoking or smoking intensity in this cohort 
(Tables 6 and 7). Furthermore, among males, using non-smokers with the highest 
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tertile of bilirubin levels (>1 mg/dL) as reference, smokers in the lowest tertile of 
bilirubin levels (<0.75 mg/dL) had a 2.86-fold increased risk of developing lung 
cancer (Table 6). Smokers with <30 and ≥30 pack-years of smoking had HRs of 
1.40 and 4.14 respectively (Table 6 and Fig. 4A). Similarly, smokers in the lowest 
tertile of bilirubin levels who smoked <10, 10-19 and ≥20 cigarettes per day had 
HRs of 1.85, 2.70 and 4.32, respectively (Table 6 and Fig. 4B). Similar results 
were found for lung cancer mortality (Table 7, Fig. 5A and 5B). In contrast, among 
females, lower serum bilirubin levels were not significantly associated with lung 
cancer incidence or mortality overall, in female smokers or in female non-smokers 
(Tables 8 and 9). Table 10 presents the rates of lung cancer incidence and 
mortality stratified by tertiles of serum bilirubin levels and corresponding risk 
estimates. We plotted the lung cancer incidence rates against subgroups of 
bilirubin levels and introduced a best-fit model. Those with bilirubin levels <0.42 
mg/dL showed more than 80% increase in lung cancer incidence rate (6.1 vs 3.27 
per 100,000 person-years, Figure 4A) and over two folds increase in mortality rate 
(4.09 vs 1.94 per 100,000 person-years, Figure 4B) compared to the subgroup 
with bilirubin levels >1.62 mg/dL. 
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Table 6. Relationship among smoking quantity, bilirubin levels and risk for lung cancer incidence by smoking 
status among male participants in the prospective cohort study 
  Men (N=202,902) 
 
Total 
 
Total bilirubin level (mg/dL) 
        
 
>1 
 
0.75-1 
 
<0.75 
 
No. 
No. of 
incidence 
HRa (95% CI) 
 
No. 
No. of 
incidence 
HRa (95% CI) 
 
No. 
No. of 
incidence 
HRa (95% CI) 
 
No. 
No. of 
incidence 
HRa (95% CI) 
Non-smoker 92,864 156 1 (Ref) 
 
35,175 64 1 (Ref) 
 
30,188 50 0.87 (0.59-1.27) 
 
27,501 42 0.85 (0.56-1.27) 
Total smokers 101,092 603 2.64 (2.19-3.18) 
 
29,632 139 1.84 (1.35-2.51) 
 
32,451 202 2.38 (1.77-3.19) 
 
39,009 262 2.86 (2.15-3.81) 
Pack-year 
               
<30 pack-years 72,153 123 1.31 (1.02-1.69) 
 
21,843 27 0.80 (0.50-1.29) 
 
23,084 47 1.37 (0.92-2.03) 
 
27,226 49 1.40 (0.94-2.07) 
≥30 pack-years 24,146 454 4.01 (3.27-4.91) 
 
6,269 108 3.14 (2.25-4.36) 
 
7,777 145 3.48 (2.54-4.77) 
 
10,100 201 4.14 (3.06-5.60) 
# of Cigarettes per day 
               
<10  31,520 106 1.55 (1.20-2.01) 
 
10,602 23 0.96 (0.58-1.57) 
 
10,270 37 1.39 (0.91-2.13) 
 
10,648 46 1.85 (1.24-2.74) 
10-19 38,866 261 2.71 (2.19-3.34) 
 
11,031 62 1.97 (1.36-2.84) 
 
12,557 91 2.58 (1.84-3.60) 
 
15,278 108 2.70 (1.95-3.72) 
≥20  26,879 221 4.29 (3.46-5.33) 
 
6,759 52 3.39 (2.31-4.96) 
 
8,374 70 3.72 (2.61-5.30) 
 
11,746 99 4.32 (3.11-5.99) 
aAdjusted for age, educational level and body mass index  
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Table 7. Relationship among smoking quantity, bilirubin levels and lung cancer mortality by smoking status 
among male participants in the prospective cohort study 
  Men (N = 202,902) 
 Total  
Total bilirubin level (mg/dL) 
  
 
>1 
 
0.75-1 
 
<0.75 
 
 
No. 
 
No. of 
mortality 
HRa (95% CI) 
 
 
 
No. 
 
No. of 
mortality 
HRa (95% CI) 
 
 
 
No. 
 
No. of 
mortality 
HRa (95% CI) 
 
 
 
No. 
 
No. of 
mortality 
HRa (95% CI) 
 
Non-smoker 92,864 98 1 (Ref) 
 
35,175 36 1 (Ref) 
 
30,188 34 1.04 (0.65-1.66) 
 
27,501 28 0.99 (0.60-1.63) 
Total smokers 101,092 478 3.24 (2.60-4.05) 
 
29,632 104 2.39 (1.63-3.50) 
 
32,451 165 3.28 (2.28-4.72) 
 
39,009 209 3.96 (2.77-5.65) 
Pack-year 
               
<30 pack-years 72,153 90 1.62 (1.20-2.18) 
 
21,843 14 0.80 (0.43-1.48) 
 
23,084 39 2.08 (1.31-3.30) 
 
27,226 37 2.01 (1.26-3.20) 
≥30 pack-years 24,146 370 4.78 (3.77-6.05) 
 
6,269 89 4.18 (2.81-6.22) 
 
7,777 119 4.56 (3.11-6.69) 
 
10,100 162 5.52 (3.81-7.99) 
# of Cigarettes per day 
               
<10  31,520 84 1.95 (1.45-2.62) 
 
10,602 14 1.05 (0.56-1.94) 
 
10,270 29 1.91 (1.17-3.14) 
 
10,648 41 2.88 (1.83-4.52) 
10-19 38,866 211 3.38 (2.65-4.32) 
 
11,031 48 2.65 (1.71-4.09) 
 
12,557 77 3.65 (2.45-5.45) 
 
15,278 86 3.75 (2.53-5.55) 
≥20  26,879 172 5.16 (4.01-6.65) 
 
6,759 42 4.64 (2.96-7.27) 
 
8,374 55 4.95 (3.24-7.57) 
 
11,746 75 5.74 (3.85-8.56) 
aAdjusted for age, educational level and body mass index  
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Table 8. Relationship among smoking quantity, bilirubin levels and risk for lung cancer incidence by smoking 
status among female participants in the prospective cohort study 
 
  Women (N = 222,758) 
 
Total 
 
Total bilirubin level (mg/dL) 
        
 
>0.82 
 
0.61-0.82 
 
<0.61 
 
No. 
No. of 
incidence 
HRa (95% CI) 
 
No. 
No. of 
incidence 
HRa (95% CI) 
 
No. 
No. of 
incidence 
HRa (95% CI) 
 
No. 
No. of 
incidence 
HRa (95% CI) 
Non-smoker 188,685 435 1 (Ref) 
 
64,488 127 1 (Ref) 
 
61,534 157 1.35 (1.06-1.73) 
 
62,663 151 1.36 (1.06-1.74) 
Total smokers 17,123 37 1.23 (0.87-1.74) 
 
4,891 11 1.55 (0.81-2.98) 
 
5,228 10 1.23 (0.64-2.35) 
 
7,004 16 1.68 (0.99-2.86) 
Pack-year 
               
<30 pack-years 14,662 13 0.61 (0.34-1.08) 
 
4,303 5 0.86 (0.32-2.34) 
 
4,403 2 0.38 (0.09-1.56) 
 
5,956 6 0.97 (0.43-2.22) 
≥30 pack-years 1,327 21 2.84 (1.82-4.43) 
 
279 4 3.16 (1.16-8.57) 
 
434 7 3.25 (1.51-6.99) 
 
614 10 3.88 (2.02-7.43) 
# of Cigarettes per day 
               
<10  10,403 16 0.89 (0.53-1.49) 
 
3,237 8 1.75 (0.81-3.75) 
 
3,201 2 0.44 (0.11-1.77) 
 
3,965 6 1.18 (0.52-2.70) 
10-19 4,054 12 1.54 (0.86-2.73) 
 
1,004 3 2.03 (0.64-6.40) 
 
1,210 2 0.93 (0.23-3.76) 
 
1,840 7 2.61 (1.21-5.61) 
≥20  1,693 8 3.02 (1.50-6.08)   382 0 N/A   475 6 8.91 (3.91-20.29)   836 2 2.03 (0.50-8.21) 
aAdjusted for age, educational level and body mass index  
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Table 9. Relationship among smoking quantity, bilirubin levels and lung cancer mortality by smoking status 
among female participants in the prospective cohort study  
  Women (N = 222,758) 
 Total  
Total bilirubin level (mg/dL) 
  
 
>0.82 
 
0.61-0.82 
 
<0.61 
 
 
No. 
 
No. of 
mortality 
HRa (95% CI) 
 
 
 
No. 
 
No. of 
mortality 
HRa (95% CI) 
 
 
 
No. 
 
No. of 
mortality 
HRa (95% CI) 
 
 
 
No. 
 
No. of 
mortality 
HRa (95% CI) 
 
Non-smoker 188,685 261 1 (Ref) 
 
64,488 85 1 (Ref) 
 
61,534 90 1.10 (0.82-1.48) 
 
62,663 86 1.10 (0.81-1.49) 
Total smokers 17,123 31 1.69 (1.16-2.46) 
 
4,891 9 1.89 (0.94-3.78) 
 
5,228 9 1.50 (0.75-3.00) 
 
7,004 13 1.88 (1.04-3.39) 
Pack-year 
               
<30 pack-years 14,662 8 0.67 (0.33-1.35) 
 
4,303 3 0.91 (0.29-2.88) 
 
4,403 1 0.27 (0.04-1.96) 
 
5,956 4 0.93 (0.34-2.55) 
≥30 pack-years 1,327 20 4.00 (2.52-6.33) 
 
279 4 4.05 (1.48-11.05) 
 
434 7 4.15 (1.91-8.99) 
 
614 9 4.44 (2.23-8.85) 
# of Cigarettes per day 
               
<10  10,403 12 1.14 (0.64-2.03) 
 
3,237 6 2.05 (0.89-4.70) 
 
3,201 1 0.30 (0.04-2.14) 
 
3,965 5 1.39 (0.56-3.43) 
10-19 4,054 11 2.25 (1.23-4.12) 
 
1,004 3 2.86 (0.90-9.05) 
 
1,210 2 1.28 (0.31-5.20) 
 
1,840 6 3.05 (1.33-7.00) 
≥20  1,693 7 4.23 (1.99-8.98)   382 0 N/A   475 5 10.49 (4.25-25.9)   836 2 2.76 (0.68-11.23) 
aAdjusted for age, educational level and body mass index  
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Table 10. Lung cancer incidence and mortality rates and adjusted HR per tertile of serum total bilirubin level 
among the male participants in the prospective cohort study by smoking status and smoking intensity 
 
Characteristics Men (N=202,902) 
 
No. of lung cancer incidence 
 
Adjusted HRa (95% CI) 
 
Incidence Rate Per 10 000 Person-Years (95% CI) 
 
Total bilirubin level (mg/dL) 
 
Total bilirubin level (mg/dL) 
 
Total bilirubin level (mg/dL) 
  >1 0.75-1 <0.75 
 
>1 0.75-1 <0.75 
 
>1 0.75-1 <0.75 
Total 215 270 324 
 
1 (Ref) 1.24 (1.03-1.51) 1.52 (1.26-1.82) 
 
4.27 (3.71-4.90) 5.79 (5.12-6.54) 6.93 (6.20-7.75) 
Non-smoker 64 50 42 
 
1 (Ref) 0.86 (0.59-1.27) 0.84 (0.56-1.26) 
 
2.56 (1.98-3.30) 2.46 (1.86-3.27) 2.35 (1.72-3.22) 
Total smokers 139 202 262 
 
1 (Ref) 1.29 (1.03-1.62) 1.55 (1.25-1.92) 
 
6.05 (5.09-7.18) 8.37 (7.27-9.64) 9.75 (8.61-11.03) 
<30 pack-years 27 47 49 
 
1 (Ref) 1.71 (1.04-2.79) 1.77 (1.09-2.89) 
 
1.57 (1.06-2.33) 2.74 (2.05-3.67) 2.61 (1.95-3.48) 
≥30 pack-years 108 145 201   1 (Ref) 1.10 (0.85-1.43) 1.31 (1.03-1.67)   22.41 (18.46-27.21) 24.85 (21.05-29.35) 27.79 (24.11-32.02) 
 
No. of lung cancer mortality 
 
Adjusted HRa (95% CI) 
 
Mortality Rate Per 10 000 Person-Years (95% CI) 
 
Total bilirubin level (mg/dL) 
 
Total bilirubin level (mg/dL) 
 
Total bilirubin level (mg/dL) 
 
>1 0.75-1 <0.75 
 
>1 0.75-1 <0.75 
 
>1 0.75-1 <0.75 
Total 147 214 253 
 
1 (Ref) 1.39 (1.12-1.72) 1.71 (1.39-2.10) 
 
2.70 (2.30-3.17) 4.11 (3.59-4.69) 4.88 (4.32-5.52) 
Non-smoker 36 34 28 
 
1 (Ref) 1.03 (0.65-1.65) 0.98 (0.59-1.61) 
 
1.34 (0.96-1.85) 1.49 (1.06-2.09) 1.43 (0.99-2.07) 
Total smokers 104 165 209 
 
1 (Ref) 1.37 (1.07-1.76) 1.66 (1.31-2.10) 
 
4.18 (3.45-5.07) 6.17 (5.30-7.19) 7.02 (6.13-8.04) 
<30 pack-years 14 39 37 
 
1 (Ref) 2.60 (1.41-4.80) 2.56 (1.38-4.74) 
 
0.77 (0.45-1.30) 2.06 (1.51-2.82) 1.80 (1.31-2.49) 
≥30 pack-years 89 119 162   1 (Ref) 1.09 (0.82-1.44) 1.32 (1.01-1.71)   16.54 (13.44-20.36) 18.02 (15.06-21.57) 20.13 (17.26-23.48) 
*Adjusted for age, educational level and body mass index      
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Figure 5. Adjusted HRs of lung cancer incidence stratified by tertiles of 
serum total bilirubin level and smoking pack-years (A) or cigarettes per day 
(B) among male participants of the prospective cohort study.   
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Figure 6. Adjusted HRs of lung cancer mortality stratified by tertiles of 
serum total bilirubin level and smoking pack-years (A) or cigarettes per day 
(B) among male participants of the prospective cohort study.   
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Figure 7. Serum total bilirubin levels and lung cancer incidence rates (A) 
and mortality rates (B) in overall males of the prospective cohort study.    
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3.1.5. The ability of bilirubin in identifying smokers with higher risk of lung cancer 
We then assessed the association between bilirubin levels and lung cancer 
incidence or mortality rate stratified by smoking status. Among females, neither 
non-smokers or smokers showed significant association, as only 17,123 (8.3%) 
participants were smokers, and there were only 37 lung cancer cases among 
them. Among males, the association was only present in smokers. Compared to 
smokers with bilirubin levels in the highest tertile, smokers with bilirubin levels in 
the middle and lowest tertiles had significantly increased lung cancer risk (HRs, 
1.29 and 1.55) and mortality (HRs, 1.37 and 1.66) (Table 10). The risk appeared 
to be stronger in light smokers: the HRs for the lowest tertile of bilirubin compared 
to the highest tertile were 1.77 for incidence and 2.56 for mortality in smokers of 
<30 pack years and 1.31 for incidence and 1.32 for mortality in smokers of ≥30 
pack years, respectively (Table 10). We also plotted the lung cancer incidence 
and mortality rates against subgroups of bilirubin levels in smokers and 
introduced a best-fit model. Subjects with bilirubin levels <0.42 mg/dL showed 
more than two folds increase in both lung cancer incidence rate (8.62 vs 3.76 per 
100,000 person-years, Figure 7A) and mortality rate (6.27 vs 3.05 per 100,000 
person-years, Figure 7B) compared to the subgroup with bilirubin levels >1.62 
mg/dL. The associations between bilirubin level as a continuous variable and both 
lung cancer incidence and lung cancer mortality were statistically significant in 
males. The logistic regression model showed a 5% (95% CI, 3%-8%, P < 0.001) 
increase in lung cancer incidence and 6% (95% CI, 3%-9%, P < 0.001) increase 
in lung cancer mortality per 0.1 mg/dL decrease in bilirubin, after adjusting for age, 
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BMI and educational level. The interaction between bilirubin levels and smoking 
status was not significant (log-likelihood test, P>0.05). 
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Figure 8. Serum total bilirubin levels and lung cancer incidence rates (A) 
and mortality rates (B) in male smokers of the prospective cohort study.   
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3.2. Discussion 
The purpose of this study is to identify biomarkers among serum 
metabolites for lung cancer early diagnosis and to assist in identifying high-risk 
individuals for lung cancer development. To our knowledge, this is the first study 
that identified serum bilirubin as a lung cancer biomarker through unbiased global 
metabolomic profiling. Furthermore, lower bilirubin was validated to confer an 
increased risk for both lung cancer incidence and lung cancer specific mortality in 
a large prospective cohort. When stratifying by smoking status, the association 
was significant only in male ever-smokers. Through this multi-stage study, we 
have identified and validated serum bilirubin as a risk predictor for lung cancer 
incidence as well as mortality in male smokers. While smoking is a strong risk 
factor for lung cancer and shows a dose-response relationship, the 
smoking-related risk is particularly high among individuals with low levels of 
serum bilirubin, a 55% increase among those with bilirubin <0.75 mg/dL. Smokers 
with ≥30 pack years had a 4-fold increase in lung cancer risk, and within this 
group, those with bilirubin of <0.75 mg/dL had a 31% higher risk compared to 
those of >1 mg/dL. The potential of using serum bilirubin to identify smokers at 
particularly high-risk for lung cancer over and above the risk associated with 
heavy smoking is an important observation. The inverse relationship between 
bilirubin levels and lung cancer can be translated into a 5% increase in lung 
cancer risk and a 6% increase in lung cancer mortality for each 0.1 mg/dL 
decrease in bilirubin levels. In most clinical settings, emphasis is placed on 
elevated bilirubin for diagnosis of liver diseases; hence low values of bilirubin are 
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generally ignored. Making use of low serum bilirubin values to counsel heavy 
smokers who are at particularly high risk for lung cancer about smoking cessation 
can be carried out easily in many clinic settings. 
Our findings may also have implications for the LDCT screening for lung 
cancer. It has been reported that LDCT screening prevented the most deaths from 
lung cancer among participants with the highest risk for lung cancer deaths − 60% 
of participants at the highest risk accounted for 88% of prevented lung-cancer 
deaths (7). Based on our results, male smokers with bilirubin level <0.75 mg/dL 
have a 66% increased risk for lung cancer mortality compared to those with 
bilirubin level >1 mg/dL, and for heavy smokers of ≥30 pack-years, the hazard 
ratio is smaller, but still significant (HR = 1.32, P < 0.001). Consideration of 
bilirubin levels might improve identifying participants with the highest risk for lung 
cancer mortality who would benefit the most from the screening, and help improve 
the specificity of LDCT screening. Furthermore, bilirubin results could be used to 
target and motivate both light and heavy smokers for smoking cessation. Indeed, 
the ability of low bilirubin in predicting high risk of lung cancer was not limited to 
smokers with ≥30 pack-years in our study. The relationship was seen for all 
smokers, regardless of pack years of smoking. 
Elevated levels of serum bilirubin have been associated with a lower risk of 
respiratory diseases and lung cancer (23, 24). The mechanism of this association 
was credited to the antioxidant and anti-inflammatory properties of bilirubin. One 
study examined the association between serum bilirubin levels and all-cause, 
cardiovascular, and cancer mortality in 10,000 Belgian individuals who had been 
56  
followed up for 10 years (40). They found that higher bilirubin within the normal 
range was associated with lower cancer mortality only in men. Another recent 
large UK cohort study showed higher bilirubin levels within the normal-range were 
associated with lower risks of respiratory diseases including chronic obstructive 
pulmonary disease (COPD), lung cancer and all-cause mortality (41). While that 
study examined risks of respiratory diseases and all-cause mortality, our study 
focused on lung cancer incidence and lung cancer specific mortality. Interestingly, 
the UK study found significant association between bilirubin and lung cancer 
incidence in both men and women, while in our study only men exhibited 
significant association. Similarly, the Belgian study also found significant inverse 
association between bilirubin and cancer mortality only in men. It should be 
pointed out that percentage (58%) of female ever-smokers in the UK study was 
much higher than those of our study (8.3%) and the Belgian study (~25%). It is 
possible that the associations found in both men and women in the UK study 
reflect largely the associations between bilirubin levels and lung cancer incidence 
in male and female smokers.  
Neither the UK nor the Belgian study performed stratified analysis of 
bilirubin and lung cancer risk by smoking status. Smoking significantly reduces 
serum bilirubin level and simply adjusting for smoking status during the analyses 
may not be sufficient to account for the effect of smoking on the association 
between bilirubin and lung cancer incidence and mortality, as adjusting for 
smoking in our study did not remove the association between bilirubin levels and 
lung cancer incidence and mortality in men. Only by examining the association in 
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smokers and non-smokers separately that we were able to detect the 
bilirubin-lung cancer associations in the subgroup of male ever-smokers. Notably, 
the association between bilirubin levels and lung cancer incidence and mortality 
rate in male ever-smokers remained strong in a series of sensitivity analyses in 
our study, including restricting bilirubin levels within the normal range, excluding 
participants who had abnormal liver enzyme assays or blood counts, or adjusting 
for more variables (drinking status, physical activity and systolic blood pressure) 
(data not shown). As bilirubin is a commonly ordered laboratory test, uncovering 
this potentially protective relationship is intriguing. This study, while in line with the 
reported conclusion, is the first to study the role of bilirubin as a risk factor for lung 
cancer mortality, to focus on the analysis in smokers in detail, and to quantify the 
hazards of low bilirubin.  
We conducted a series of sensitivity analyses to strengthen our conclusion. 
We excluded participants with lung cancer diagnosed within 3 years of cohort 
enrollment. We restricted bilirubin levels within normal range, excluding 
participants with abnormal liver enzymes or blood counts. Additional variables 
(drinking status, physical activity and systolic blood pressure) were adjusted in the 
multivariable models. Results essentially remained unchanged after all of the 
above sensitivity analyses were carried out.  
Recently, several research groups had applied metabolomic profiling of 
serum/plasma to unveil metabolic alterations associated with lung cancer. Hori 
and colleagues performed metabolomic profiling of serum samples in a Japanese 
case-control study using gas chromatography/mass spectrometry (GC/MS), 
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which detected a total of only 58 metabolites in serum (45). Among these, the 
levels of 23 metabolites were altered in lung cancer patients compared to healthy 
controls (45). In another study conducted in Japan, Maeda et al. studied 21 
plasma amino acids in NSCLC patients by liquid chromatography/mass 
spectrometry (LC/MS) and showed that differences in the amino acid profiles 
could be used for screening NSCLC (35). Jordan and colleagues used nuclear 
magnetic resonance (NMR) to measure 21 metabolites and showed the potential 
of serum metabolomics to differentiate between lung cancer subtypes and 
between patients and controls (34). However, these studies were limited by the 
small number of metabolites detected. Our global unbiased metabolomic profiling 
approach identified 403 known metabolites from different stages of lung cancer, 
yielding a comprehensive picture of the metabolic profile changes associated with 
cancer progression. Validated with two additional study sets, bilirubin was found 
and confirmed as the most significant biomarker for lung cancer, which was 
further validated prospectively in a large cohort. 
A few potential limitations should be considered in the interpretation of our 
findings. First, while we observed significant inverse associations between serum 
bilirubin levels and lung cancer in male smokers, the associations were not 
statistically significant in female smokers, which was most likely due to the lack of 
power resulting from a small number of female smokers (8.3% of total females) 
and very few number of lung cancer cases (n=37) among them. Second, although 
we observed an inverse relationship between bilirubin levels and lung cancer risk, 
the causality of the association remains unclear. Low bilirubin level could be a 
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consequence of cancer rather than a predisposing factor. It is noteworthy that the 
significant risk remained after we excluded lung cancer occurring within three 
years of the bilirubin tests. Third, only the bilirubin data at the time of enrollment 
were analyzed. In a subset of subjects that had two bilirubin tests performed 
longitudinally, we found highly correlative data, implying the stability of total 
bilirubin results over time.  
In summary, low levels of serum bilirubin are associated with higher risk for 
lung cancer incidence and mortality in male smokers and can be used to identify 
higher risk smokers for lung cancer development and mortality. Future 
prospective studies that incorporate this variable into NLST selection criteria to 
fully assess its potential use for LDCT screening are warranted. 
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3.3. Clinical Laboratory Tests and Lung Cancer Clinical Outcome 
3.3.1. Patient characteristics  
This study included 2,675 NSCLC patients, among whom 623 (23.3%) 
were early stage and 2,052 (77.6%) were advanced stage patients (Table 11). 
Among early stage NSCLC patients, 313 (50.2%) were men and 310 (49.8%) 
were women, with a mean age of 66.8 years. The median survival time (MST) 
was 62.7 months, with a median follow-up time (MFT) of 36.8 months. Over 90% 
of the patients had a history of smoking, with 316 (50.7%) being former smokers 
and 246 (39.5%) being current smokers or having quit within one year prior to 
diagnosis. Three Hundred and ninety-six (63.6%) of them had stage I NSCLC, 
while the remaining 227 (36.4%) had stage II disease. Among them, over half 
(51.8%) had adenocarcinoma and 33.4% had squamous cell carcinoma. Among 
2,052 advanced stage patients, 1,125 (54.8%) were men and 927 (45.2%) were 
women, with a mean age of 61.7 years. The MST and MFT were 13.8 and 13.0 
months respectively. Eight hundred and nineteen (39.9%) of them were former 
smokers and 880 (42.9%) were current smokers or had quit within one year prior 
to diagnosis. There were 477 (23.2%) stage IIIA, 277 (13.5%) stage IIIB and 
1,298 (63.3%) stage IV patients. Patients with adenocarcinoma or squamous 
cancer carcinoma represented 55.8% (n=1,146) or 22.1% (n=454) of all advanced 
stage patients, respectively. Among them, 1,192 (58.1%) received definitive 
chemotherapy, 978 of which were platinum-based. There was no statistically 
significant association between the routine pre-treatment laboratory tests 
investigated and recurrence or survival of early stage NSCLC patients (data not 
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shown), therefore, only results of advanced stage NSCLC patients are presented 
in details. 
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Table 11. Host characteristics of overall, early stage and late stage NSCLC 
patients  
 
Variables All Stage Early Stage Late Stage 
N (%) 
Mean age, y (SD)  62.9 (11.0)  66.8 (10.0)  61.7 (11.0) 
Sex 
   
Male 1438 (53.8) 313 (50.2) 1125 (54.8) 
Female 1237 (46.2) 310 (49.8) 927 (45.2) 
Race 
   
White 2201 (82.3) 535 (85.9) 1666 (81.2) 
Hispanic 107 (4.0) 19 (3.0) 88 (4.3) 
Black 367 (13.7) 69 (11.1) 298 (14.5) 
Smoking status 
   
Never 413 (15.4) 61 ( 9.8) 352 (17.2) 
Former 1135 (42.4) 316 (50.7) 819 (39.9) 
Current 1126 (42.1) 246 (39.5) 880 (42.9) 
Clinical stage 
   
Stage I 396 (14.8) 396 (63.6) 
 
Stage II 227 (8.5) 227 (36.4) 
 
Stage IIIA 477 (17.8) 
 
477 (23.2) 
Stage IIIB 277 (10.4) 
 
277 (13.5) 
Stage IV 1298 (48.5) 
 
1298 (63.3) 
Histology 
   
Adenocarcinoma 1469 (54.9) 323 (51.8) 1146 (55.8) 
Squamous 662 (24.7) 208 (33.4) 454 (22.1) 
Others 544 (20.3) 92 (14.8) 452 (22.0) 
Performance Status (ECOG score) 
   
0 539 (20.1) 153 (24.6) 386 (18.8) 
1 1271 (47.5) 251 (40.3) 1020 (49.7) 
2-4 421 (15.7) 63 (10.1) 358 (17.4) 
Unknown 444 (16.6) 156 (25.0) 288 (14.0) 
Histology grade 
   
Well differentiated 130 (4.9) 64 (10.3) 66 (3.2) 
Moderately differentiated 474 (17.7) 180 (28.9) 294 (14.3) 
Poorly differentiated and undifferentiated 1128 (42.2) 258 (41.4) 870 (42.4) 
Unknown 943 (35.3) 121 (19.4) 822 (40.1) 63  
No. of metastasis 
   
0 1537 (57.5) 622 (99.8) 915 (44.6) 
1 742 (27.7) 1 ( 0.2) 741 (36.1) 
2 262 ( 9.8) 0 262 (12.8) 
≥3 134 ( 5.0) 0 134 ( 6.5) 
Surgery 
   
No 2080 (77.8) 200 (32.1) 1880 (91.6) 
Yes 595 (22.2) 423 (67.9) 172 (8.4) 
Radiation 
   
No 1941 (72.6) 472 (75.8) 1469 (71.6) 
Yes 734 (27.4) 151 (24.2) 583 (28.4) 
Chemotherapy 
   
No 1297 (48.5) 437 (70.1) 860 (41.9) 
Yes 1378 (51.5) 186 (29.9) 1192 (58.1) 
Chemoradiation 
   
No 2174 (81.3) 577 (92.6) 1597 (77.8) 
Yes 501 (18.7) 46 (7.4) 455 (22.2) 
MST, mo 18.1 62.7 13.8 
MFT, mo 16 36.8 13 
Abbreviations: MST, median survival time; MFT, median follow-up time    
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3.3.2. Association of pre-treatment laboratory test levels with survival of 
advanced stage NSCLC patients 
Among the seven routine clinical pre-treatment serum laboratory tests 
analyzed, low albumin, high ALP and high LDH were found statistically 
significantly associated with both 2-year and 5-year survival of advanced stage 
NSCLC patients subsequently treated with platinum-based chemotherapy (Table 
12), after adjusting for other factors, i.e. age, gender, ethnicity, smoking status, 
clinical stage and treatment regimen. Lower than normal (<3.5 g/dL) serum 
pre-treatment albumin levels were associated with 47% and 39% increase risk of 
death at 2-year and 5-year survival of advanced stage NSCLC patients treated 
with platinum-based chemotherapy. This corresponded to a MST of 11.6 months 
among those with low serum albumin levels and a MST of 17.1 months among 
those with normal serum albumin levels (log-rank test P < 0.01) (Figure 8A and 
9A). Similarly, advanced stage NSCLC patients with elevated and higher than 
normal serum ALP levels (>126 IU/L) or LDH levels (>618 IU/L) were at 31% or 60% 
increased risk of death at two years than those with normal serum ALP or LDH 
level, respectively. Similar increases were also found for 5-year survival among 
those patients (Table 12). MST for patients with normal serum ALP levels was 
17.4 months compared to 12.6 months for those with higher than normal ALP 
levels (log-rank test P < 0.0001) (Figure 8B and 9B). Similarly, MST for patients 
with normal serum LDH levels was 18.0 months compared to 12.3 months for 
those with higher than normal LDH levels (log-rank test P < 0.0001) (Figure 8C 
and 9C).
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Table 12. Laboratory test levels associated with 2-year and 5-year survival in advanced NSCLC patients treated 
with platinum-based chemotherapy 
 
Lab Test 
2-year survival 
 
5-year survival 
Alive, Dead, Adjusted HRa 
P MST 
Log-rank 
P  
Alive, Dead, Adjusted HRa 
P MST 
Log-rank 
P N (%) N (%) (95% CI) N (%) N (%) (95% CI) 
Albumin (g/dL) 
             
≥3.5 328 (37.88) 538 (62.12) 1 (reference) 
 
17.1 
  
170 (19.63) 696 (80.37) 1 (reference) 
 
17.1 
 
<3.5 19 (18.63) 83 (81.37) 1.47 (1.15-1.87) 0.002 11.6 5.75E-07 
 
9 (8.82) 93 (91.18) 1.39 (1.11-1.75) 0.004 11.6 1.31E-06 
ALP (IU/L) 
             
38-126 302 (38.77) 477 (61.23) 1  (reference) 
 
17.4 
  
154 (19.77) 625 (80.23) 1  (reference) 
 
17.4 
 
>126 47 (23.98) 149 (76.02) 1.31 (1.08-1.58) 0.006 12.6 1.16E-05 
 
25 (12.76) 171 (87.24) 1.24 (1.04-1.48) 0.01 12.6 6.06E-05 
LDH (IU/L) 
             
≤618 299 (39.45) 459 (60.55) 1 (reference) 
 
18.0 
  
155 (20.45) 603 (79.55) 1 (reference) 
 
18.0 
 
>618 47 (21.96) 167 (78.04) 1.60 (1.34-1.92) 3.51E-07 12.3 5.29E-09 
 
24 (11.21) 190 (88.79) 1.56 (1.32-1.85) 1.74E-07 12.3 2.58E-08 
Abbreviations: ALP, ; LDH,  
a Adjusted for age, gender, ethnicity, smoking status, clinical stage, performance status and treatment with radiation. 
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Figure 9. Kaplan-Meier 2-year survival curves for patients with advanced 
NSCLC treated with platinum-based chemotherapy grouped by individual 
lab test level: (A) Albumin, (B) ALP, (C) LDH.  67  
  
 
Figure 10. Kaplan-Meier 5-year survival curves for patients with advanced 
NSCLC treated with platinum-based chemotherapy grouped by individual 
lab test level: (A) Albumin, (B) ALP, (C) LDH. 
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3.3.3. Cumulative effects of unfavorable laboratory test levels  
We conducted joint analysis to investigate whether advanced stage 
NSCLC patients with more unfavorable pre-treatment laboratory test levels were 
more likely to suffer from death, and the results were statistically significant (Table 
13). Compared to those with none of the three adverse laboratory test levels for 
albumin, ALP and LDH, advanced stage NSCLC patients who had one adverse 
laboratory test level had a 34% increase in risk of death at 2 years (HR = 1.34, 95% 
CI: 1.12-1.60, P < 0.001). Those with more than one adverse laboratory test 
levels were two folds more likely to die at 2 years (HR = 2.00, 95% CI: 1.57-2.56, 
P < 0.0001). Similar results were also found for 5-year survival of these patients. 
The corresponding MSTs were 19.6, 14.0 and 10.0 months for advanced stage 
NSCLC patients with 0, 1 and ≥2 unfavorable pre-treatment laboratory test levels 
(log-rank test P < 0.0001) (Figure 10A and 11A). 
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Table 13. Cumulative effect of unfavorable laboratory test levels associated with 2-year and 5-year survival in 
advanced NSCLC patients treated with platinum-based chemotherapy  
 
No. of Adverse 
Lab Test 
2-year survival 
 
5-year survival 
Alive, 
N (%) 
Dead, 
N (%) 
Adjusted HRa 
(95% CI) 
P MST 
Log-rank 
P  
Alive, 
N (%) 
Dead, 
N (%) 
Adjusted HRa 
(95% CI) 
P MST 
Log-rank 
P 
0 247 (43.33) 323 (56.67) 1 (reference) 
 
19.6 
  
130 (22.81) 440 (77.19) 1 (reference) 
 
19.6 
 
1 82 (28.28) 208 (71.72) 1.34 (1.12-1.60) 1.29E-03 14.0 
  
39 (13.45) 251 (86.55) 1.32 (1.12-1.55) 6.97E-04 14.0 
 
≥2 14 (13.73) 88 (86.27) 2.00 (1.57-2.56) 2.68E-08 10.0 1.90E-14 
 
9 (8.82) 93 (91.18) 1.80 (1.43-2.27) 7.34E-07 10.0 1.17E-12 
a Adjusted for age, gender, ethnicity, smoking status, clinical stage, performance status and treatment with radiation. 
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Figure 11. Kaplan-Meier 2-year survival curves for patients with advanced 
NSCLC treated with platinum-based chemotherapy grouped by cumulative 
effect of adverse lab test (A) and lab-test based risk score (B).   
71  
   
Figure 12. Kaplan-Meier 5-year survival curves for patients with advanced 
NSCLC treated with platinum-based chemotherapy grouped by cumulative 
effect of adverse lab test (A) and lab-test based risk score (B).  
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3.3.4. Lab-test based risk score associated with survival of advanced NSCLC 
patients 
We generated a risk score based on the three pre-treatment serum 
laboratory test levels associated with survival of advanced stage NSCLC patients 
treated with platinum-based chemotherapy. Compared to those with a low-risk 
score, patients with a high-risk score had 49% increased risk of death at two 
years (HR = 1.49, 95% CI: 1.26-1.75, P < 0.0001). Similar results were found for 
5-year survival of those patients (Table 14). Kaplan-Meier survival analysis 
showed that the corresponding MST was 19.6 months for those with a low-risk 
score and 12.8 months for those with a high-risk score (log-rank test P < 0.0001) 
(Figure 10B and 11B). 
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Table 14. Lab-test based risk score associated with 2-year and 5-year survival in advanced NSCLC patients treated 
with platinum-based chemotherapy 
 
 
2-year survival 
 
5-year survival 
Risk Score 
Alive, Dead, Adjusted HRa 
P MST 
Log-rank 
 
Alive, Dead, Adjusted HRa 
P MST 
Log-rank 
N (%) N (%) (95% CI) P N (%) N (%) (95% CI) P 
Low 247 (43.33) 323 (56.67) 1 (reference) 
 
19.6 
  
130 (22.81) 440 (77.19) 1 (reference) 
 
19.6 
 
High 96 (24.49) 296 (75.51) 1.49 (1.26-1.75) 1.71E-06 12.8 1.30E-11 
 
48 (12.24) 344 (87.76) 1.42 (1.23-1.64) 2.28E-06 12.8 7.92E-11 
a Adjusted for age, gender, ethnicity, smoking status, clinical stage, performance status and treatment with radiation. 
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3.4. Discussion 
In this study, we evaluated seven serum pre-treatment clinical laboratory 
tests indicative of overall metabolic status and investigated their prognostic values 
in 622 early stage and 2,053 advanced stage NSCLC patients. While we did not 
observe any significant associations between any of these laboratory test levels 
and recurrence or survival of early stage NSCLC patients, we identified and 
confirmed three serum pre-treatment clinical laboratory test levels (lower than 
normal levels of albumin, higher than normal levels of ALP and LDH) as 
prognostic factors for advanced stage NSCLC patients treated with 
platinum-based chemotherapy. Not only was each of the three clinical laboratory 
tests significantly associated with overall survival among patients with advanced 
stage NSCLC treated with platinum-based chemotherapy, there was also a 
significant cumulative effect – those with two or more than two adverse laboratory 
test levels were two-fold more likely to die at two years compared to those with 
none of the adverse laboratory test levels, corresponding to a MST of 10.0 
months and 19.6 months, respectively. 
Serum albumin level has been used as a biomarker for long-term 
nutritional status (46, 47). Serum albumin is produced in the liver and is the most 
abundant protein in human plasma/serum. Its major functions include maintaining 
the intravascular oncotic pressure of the blood compartment, transporting 
molecules of low water solubility and serving as a free radical scavenger (48). In 
adults, normal range of serum albumin is 3.5 to 5.0 g/dL. Low serum albumin level 
(<3.5 g/dL in adults), also known as hypoalbuminemia, may be caused by liver 
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diseases, malabsorption, pregnancy, genetic variations, as well as cancers. 
Albumin level is often used as an indicator for liver disease or acute infection (49, 
50). It’s also closely correlated with malnutrition, which commonly occurs in 
cancer patients resulting from the host response to the tumor as well as to 
therapeutic treatments. Studies have investigated the association of malnutrition 
with several clinical outcomes among cancer patients, including quality of life 
(QOL), response to treatment as well as overall survival. Malnutrition has been 
found to be associated with worse overall clinical outcomes, which includes worse 
QOL and shorter overall survival among cancer patients. In addition, 
hypoalbuminemia has also been shown to be associated with worse clinical 
outcomes in cancer patients. Studies have shown that low serum albumin level is 
a negative prognostic factor in several kinds of malignancies, including colorectal 
cancer (51, 52), gastric cancer (53), pancreatic cancer and breast cancer (54).  
Alkaline phosphatase (ALP) is a ubiquitous enzyme present in all human 
body tissues, catalyzing hydrolysis of phosphate esters and removing phosphate 
groups (also called “dephosphorylation”) from different types of molecules in an 
alkaline environment (55). There are several different ALP isoenzymes, 
depending on where it is produced in the body, e.g., hepatic ALP, placenta ALP or 
bone ALP isoenzyme, etc. Among these, ALP levels are highest in liver and bone 
tissues (56). Serum total ALP is often measured as part of routine liver panel tests 
or when presented with symptoms of liver or bone disorders to screen for a variety 
of liver or bone disorders, including extrahepatic bile obstruction, intrahepatic 
cholestasis, hepatitis, and bone disorders, e.g. Paget's disease, etc (56). Serum 
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total ALP levels have been shown to be elevated in several metastatic 
malignancies (57, 58). Of note, bone-specific alkaline phosphatase (bALP), which 
is produced by osteoblasts, is an indicator of osteoblastic activity and a marker of 
bone formation. bALP levels have been shown to be significantly elevated in 
patients with solid malignancies experiencing metastases to the bone (57-60). 
Several studies have examined bALP as a potential marker to detect occult bone 
metastases in patients with lung cancer (61-63). In NSCLC, patients with skeletal 
metastases had significantly higher levels of bALP than those without skeletal 
metastases (64). Moreover, Brown et. al showed that among 238 patients with 
NSCLC or other solid tumors, high baseline serum bALP levels were significantly 
associated with an increased risk of adverse outcomes, including skeletal-related 
events (SREs), disease progression, and overall survival. Patients with high bALP 
levels had a 1.5-fold increased risk of death (RR = 1.53, 95% CI: 1.15-2.03, P = 
0.003) (57). In their study, serum bALP levels were assessed using a chemical 
inhibition and differential inactivation assay (57, 65). While the results are 
consistent with our finding and have a similar magnitude of relative risk, their 
analysis was conducted on pooled NSCLC and other solid tumors together, 
presumably because of the small sample size of NSCLC patients (N = 115). With 
978 advanced stage NSCLC patients treated with platinum-based chemotherapy 
in our study, our results may reflect a more accurate risk estimate and are more 
statistically significant (HR = 1.38, P < 0.001). However, in our study, we didn’t 
measure the levels of different ALP isoenzymes, and rather only assessed overall 
serum ALP levels. 
77  
Lactate dehydrogenase (LDH) is a glycolytic enzyme involved in the 
conversion of pyruvate, which is the final product of the glycolysis pathway, and 
lactate. LDH is ubiquitously expressed in human body cells and serves as a 
general marker for tissue injuries since it is commonly released from the cells to 
blood after tissue damage (36). Elevated serum LDH levels may be caused by 
many pathologic conditions, including hemolytic anemia, myocardial infarction, 
liver disease, pulmonary disease, kidney disease and many types of malignancies, 
as cancer cells have a higher turnover rate (36). In addition, cancer cells have 
been long known to reprogram their energy metabolism towards glycolysis even 
under aerobic conditions, which was first observed and reported by Otto Warburg 
in the 1930s (66, 67). Elevated serum LDH levels have been shown to be 
associated with tumor mass, tumor aggressiveness and unfavorable prognosis in 
several malignancies (68-70). Moreover, several studies have identified serum 
LDH levels as a significant variable associated with survival in patients with 
NSCLC as well (71, 72). 
Our study adds significant value to the current literature body. First, this is 
one of the largest studies investigating the prognostic values of pre-treatment 
clinical laboratory test levels on NSCLC patients’ outcomes, thus statistically 
powered to reveal significant associations. Moreover, of the three laboratory tests 
identified (albumin, ALP and LDH), we found that not only did each of their 
pre-treatment level affect survival of advanced stage NSCLC patients treated with 
platinum-based chemotherapy, cumulatively patients with more adverse tests also 
had worse overall survival. Furthermore, compared to other large studies 
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investigating the roles of clinical laboratory test levels in NSCLC, our study has 
the advantage that all patients were recruited from the same institution, thus 
offering a more homogenous population in terms of quality of diagnosis, treatment, 
laboratory test techniques and reference values used. These findings also have 
practical importance in the clinical setting. Since these laboratory tests are 
inexpensive, minimally invasive for the patients and routinely performed in the 
clinical setting, their values can be easily assessed and evaluated. There are also 
limitations with our study. Although all laboratory test levels were measured before 
treatment, this study was designed retrospectively, therefore is susceptible to the 
limitations of possible selection bias and reverse causation. Future prospective 
studies investigating the prognostic values of clinical laboratory tests on NSCLC 
outcomes are warranted. 
In conclusion, in this study, we have utilized the large NSCLC patient 
population at the University of Texas MD Anderson Cancer Center, and found 
lower than normal albumin levels, higher than normal levels of ALP and LDH are 
all significant adverse prognostic factors for advanced stage NSCLC patients 
treated with platinum-based chemotherapy, both individually and cumulatively. 
Our results suggested that pre-treatment clinical laboratory test levels could be 
utilized to enhance predictions of survival among advanced stage NSCLC 
patients treated with platinum-based chemotherapy. 
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Chapter 4. Conclusions   
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In conclusion, our studies have identified clinically relevant novel serum 
biomarkers for lung cancer early diagnosis and clinical outcome. Through our 
multi-phase study comprised of global metabolomic profiling and prospective 
validation in a large cohort, we have identified and validated bilirubin as a risk 
predictor for lung cancer incidence as well as mortality in smokers. Our results 
suggested that low serum bilirubin levels can be used to identify higher risk 
smokers for lung cancer. Addition of this variable into National Lung Screening 
Trial (NLST) selection criteria for low-dose computed tomography (LDCT) 
screening might help identify higher risk smokers who would benefit more from 
LDCT screening and reduce false positives. We have also found that three 
pre-treatment clinical laboratory test levels indicative of metabolic status were 
both individually and jointly associated with overall survival among advanced 
stage NSCLC patients treated with platinum-based chemotherapy. These tests 
could further be utilized to enhance predictions of survival among advanced stage 
NSCLC patients treated with platinum-based chemotherapy.  
Taken together, our results suggested that metabolic alterations associated 
with lung cancer could serve as novel serum biomarkers with clinical significance 
for both lung cancer early detection and clinical outcome. With future prospective 
validation studies, these biomarkers could be applied to the clinics to screen for 
lung cancer at an early stage and to predict clinical outcome. 
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Chapter 5. Future Directions 
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In the current studies, we investigated global metabolomic profiles of lung 
cancer patients and matched controls and identified bilirubin as a biomarker for 
lung cancer early diagnosis, which can be used to identify higher risk smokers for 
lung cancer. For the future studies, our group is planning to determine the 
sensitivity, specificity, positive predictive value and negative predictive value of 
bilirubin as a lung cancer biomarker, and to incorporate bilirubin with other known 
lung cancer risk factors into a risk prediction model for lung cancer risk prediction. 
It would be also interesting to further conduct other “omic” profilings in these 
samples, e.g. genomic, transcriptomic and proteomic profiling to identify 
biomarkers at DNA, RNA and protein levels. Moreover, it would be of great 
interest and value to correlate our metabolomics profiling data with these other 
“omics” data to investigate the correlations among DNA, RNA, protein and 
metabolite levels to identify and elucidate novel molecular pathways underlying 
lung cancer development. In the future, we will also determine the metabolomic 
profiles among lung cancer patients with different prognosis to identify novel 
prognostic biomarkers for lung cancer clinical outcomes.  
Our studies have also identified three clinical laboratory test levels as 
biomarkers for advanced stage non-small cell lung cancer patients treated with 
platinum-based chemotherapy. While this is one of the largest studies so far 
investigating the association between clinical laboratory test levels and NSCLC 
clinical outcomes, we will seek collaboration in other independent patient 
populations with similarly detailed information on epidemiological and clinical 
follow-up data as well as data on clinical laboratory test levels, to validate our 
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findings. In addition, we will do the meta-analysis to further validate our results. In 
the meanwhile, prospective studies, in which clinical laboratory test levels of 
newly diagnosed NSCLC patients are recorded and the clinical outcomes of these 
patients are followed up prospectively would significantly provide further support 
to the research findings. Lastly, we will incorporate the clinical laboratory test 
levels and other NSCLC prognostic factors to build a prediction model for NSCLC 
patients’ survival prediction.   
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Appendix B: Supplementary table  
 
List of the 306 metabolites passing QC and their belonging pathways 
Biochemical Super-pathway Sub-pathway 
1,2-propanediol Lipid Ketone bodies 
1,5-anhydroglucitol (1,5-AG) Carbohydrate 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
1,6-anhydroglucose Carbohydrate 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
1,7-dimethylurate Xenobiotics Xanthine metabolism 
10-heptadecenoate (17:1n7) Lipid Long chain fatty acid 
10-nonadecenoate (19:1n9) Lipid Long chain fatty acid 
12-HETE Lipid Eicosanoid 
13-HODE + 9-HODE Lipid Fatty acid, monohydroxy 
13-methylmyristic acid Lipid Fatty acid, branched 
17-methylstearate Lipid Fatty acid, branched 
1-arachidonoyl-GPC* (20:4)* Lipid Lysolipid 
1-arachidonoyl-GPE* (20:4)* Lipid Lysolipid 
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1-arachidonoyl-GPI* (20:4)* Lipid Lysolipid 
1-docosahexaenoyl-GPC* (22:6)* Lipid Lysolipid 
1-docosapentaenoyl-GPC* (22:5)* Lipid Lysolipid 
1-eicosatrienoyl-GPC* (20:3)* Lipid Lysolipid 
1-heptadecanoyl-GPC (17:0) Lipid Lysolipid 
1-linoleoylglycerol (18:2) Lipid Monoacylglycerol 
1-linoleoyl-GPC (18:2) Lipid Lysolipid 
1-linoleoyl-GPE (18:2)* Lipid Lysolipid 
1-methyladenosine Nucleotide Purine metabolism, adenine containing 
1-myristoyl-GPC (14:0) Lipid Lysolipid 
1-oleoylglycerol (18:1) Lipid Monoacylglycerol 
1-oleoyl-GPC (18:1) Lipid Lysolipid 
1-oleoyl-GPE (18:1) Lipid Lysolipid 
1-palmitoleoyl-GPC* (16:1)* Lipid Lysolipid 
1-palmitoylglycerol (16:0) Lipid Monoacylglycerol 
1-palmitoyl-GPC (16:0) Lipid Lysolipid 
1-palmitoyl-GPE (16:0) Lipid Lysolipid 
1-palmitoyl-GPI* (16:0)* Lipid Lysolipid 
1-palmitoylplasmenylethanolamine* Lipid Lysolipid 
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1-pentadecanoylglycerophosphocholine* Lipid Lysolipid 
1-stearoylglycerol (18:0) Lipid Monoacylglycerol 
1-stearoyl-GPC (18:0) Lipid Lysolipid 
1-stearoyl-GPE (18:0) Lipid Lysolipid 
1-stearoyl-GPI (18:0) Lipid Lysolipid 
2-aminobutyrate Amino acid Butanoate metabolism 
2-arachidonoyl-GPC* (20:4)* Lipid Lysolipid 
2-arachidonoyl-GPE* (20:4)* Lipid Lysolipid 
2-ethylhexanoic acid Xenobiotics Chemical 
2-hydroxybutyrate (AHB) Amino acid Cysteine, methionine, SAM, taurine metabolism 
2-hydroxyglutarate Lipid Fatty acid, dicarboxylate 
2-hydroxyisobutyrate Amino acid Valine, leucine and isoleucine metabolism 
2-hydroxypalmitate Lipid Fatty acid, monohydroxy 
2-hydroxystearate Lipid Fatty acid, monohydroxy 
2-linoleoyl-GPC* (18:2)* Lipid Lysolipid 
2-linoleoyl-GPE* (18:2)* Lipid Lysolipid 
2-methylbutyroylcarnitine (C5) Amino acid Valine, leucine and isoleucine metabolism 
2-oleoyl-GPC* (18:1)* Lipid Lysolipid 
2-oleoyl-GPE* (18:1)* Lipid Lysolipid 
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2-palmitoyl-GPC* (16:0)* Lipid Lysolipid 
2-palmitoyl-GPE* (16:0)* Lipid Lysolipid 
2-pyrrolidinone Xenobiotics Chemical 
2-stearoyl-GPC* (18:0)* Lipid Lysolipid 
3-(4-hydroxyphenyl)lactate (HPLA) Amino acid Phenylalanine & tyrosine metabolism 
3-carboxy-4-methyl-5-propyl-2-furanpropanoate 
(CMPF) 
Lipid Fatty acid, dicarboxylate 
3-dehydrocarnitine* Lipid Carnitine metabolism 
3-hydroxy-2-ethylpropionate Amino acid Valine, leucine and isoleucine metabolism 
3-hydroxybutyrate (BHBA) Lipid Ketone bodies 
3-hydroxyisobutyrate Amino acid Valine, leucine and isoleucine metabolism 
3-hydroxylaurate Lipid Fatty acid, monohydroxy 
3-indoxyl sulfate Amino acid Tryptophan metabolism 
3-methoxytyrosine Amino acid Phenylalanine & tyrosine metabolism 
3-methyl-2-oxobutyrate Amino acid Valine, leucine and isoleucine metabolism 
3-methyl-2-oxovalerate Amino acid Valine, leucine and isoleucine metabolism 
3-methylhistidine Amino acid Histidine metabolism 
4-acetamidobutanoate Amino acid Guanidino and acetamido metabolism 
4-androsten-3beta,17beta-diol disulfate 1* Lipid Sterol/Steroid 
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4-androsten-3beta,17beta-diol disulfate 2* Lipid Sterol/Steroid 
4-hydroxyphenylacetate Amino acid Phenylalanine & tyrosine metabolism 
4-methyl-2-oxopentanoate Amino acid Valine, leucine and isoleucine metabolism 
5-dodecenoate (12:1n7) Lipid Medium chain fatty acid 
5-oxoproline Amino acid Glutathione metabolism 
7-HOCA Lipid Sterol/Steroid 
acetylcarnitine (C2) Lipid Carnitine metabolism 
acetylphosphate Energy Oxidative phosphorylation 
adrenate (22:4n6) Lipid Long chain fatty acid 
ADSGEGDFXAEGGGVR* Peptide Fibrinogen cleavage peptide 
alanine Amino acid Alanine and aspartate metabolism 
allantoin Nucleotide Purine metabolism, urate metabolism 
alpha-hydroxyisovalerate Amino acid Valine, leucine and isoleucine metabolism 
alpha-ketoglutarate Energy Krebs cycle 
alpha-tocopherol Cofactors and vitamins Tocopherol metabolism 
andro steroid monosulfate 2* Lipid Sterol/Steroid 
androsterone sulfate Lipid Sterol/Steroid 
arabinose Carbohydrate Nucleotide sugars, pentose metabolism 
arabitol Carbohydrate Nucleotide sugars, pentose metabolism 
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arachidonate (20:4n6) Lipid Long chain fatty acid 
arginine Amino acid Urea cycle; arginine-, proline-, metabolism 
ascorbate (Vitamin C) Cofactors and vitamins Ascorbate and aldarate metabolism 
asparagine Amino acid Alanine and aspartate metabolism 
aspartate Amino acid Alanine and aspartate metabolism 
aspartylphenylalanine Peptide Dipeptide 
azelate (nonanedioate; C9) Lipid Fatty acid, dicarboxylate 
benzoate Xenobiotics Benzoate metabolism 
beta-alanine Amino acid Alanine and aspartate metabolism 
beta-hydroxyisovalerate Amino acid Valine, leucine and isoleucine metabolism 
betaine Amino acid Glycine, serine and threonine metabolism 
bilirubin Cofactors and vitamins Hemoglobin and porphyrin metabolism 
bilirubin (E,E)* Cofactors and vitamins Hemoglobin and porphyrin metabolism 
bradykinin, des-arg(9) Peptide Polypeptide 
butyrylcarnitine (C4) Lipid Fatty acid metabolism (also BCAA metabolism) 
caffeine Xenobiotics Xanthine metabolism 
campesterol Lipid Sterol/Steroid 
caprate (10:0) Lipid Medium chain fatty acid 
caproate (6:0) Lipid Medium chain fatty acid 
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caprylate (8:0) Lipid Medium chain fatty acid 
carnitine Lipid Carnitine metabolism 
catechol sulfate Xenobiotics Benzoate metabolism 
C-glycosyltryptophan* Amino acid Tryptophan metabolism 
cholesterol Lipid Sterol/Steroid 
choline Lipid Glycerolipid metabolism 
cis-4-decenoyl carnitine Lipid Carnitine metabolism 
cis-aconitate Energy Krebs cycle 
citrate Energy Krebs cycle 
citrulline Amino acid Urea cycle; arginine-, proline-, metabolism 
cortisol Lipid Sterol/Steroid 
cortisone Lipid Sterol/Steroid 
creatine Amino acid Creatine metabolism 
creatinine Amino acid Creatine metabolism 
cyclo(phe-phe) Peptide Dipeptide 
cysteine Amino acid Cysteine, methionine, SAM, taurine metabolism 
cystine Amino acid Cysteine, methionine, SAM, taurine metabolism 
decanoylcarnitine (C10) Lipid Carnitine metabolism 
dehydroisoandrosterone sulfate (DHEA-S) Lipid Sterol/Steroid 
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deoxycarnitine Lipid Carnitine metabolism 
deoxycholate Lipid Bile acid metabolism 
dihomolinoleate (20:2n6) Lipid Long chain fatty acid 
dihomolinolenate (20:3n3 or 3n6) Lipid Essential fatty acid 
dimethylarginine (ADMA + SDMA) Amino acid Urea cycle; arginine-, proline-, metabolism 
dimethylglycine Amino acid Glycine, serine and threonine metabolism 
docosadienoate (22:2n6) Lipid Long chain fatty acid 
docosahexaenoate (DHA; 22:6n3) Lipid Essential fatty acid 
docosapentaenoate (DPA; 22:5n3) Lipid Essential fatty acid 
docosapentaenoate (n6 DPA; 22:5n6) Lipid Essential fatty acid 
dodecanedioate (C12) Lipid Fatty acid, dicarboxylate 
DSGEGDFXAEGGGVR* Peptide Fibrinogen cleavage peptide 
eicosapentaenoate (EPA; 20:5n3) Lipid Essential fatty acid 
eicosenoate (20:1n9 or 1n11) Lipid Long chain fatty acid 
epiandrosterone sulfate Lipid Sterol/Steroid 
erythritol Xenobiotics Sugar, sugar substitute, starch 
erythronate* Carbohydrate Aminosugars metabolism 
ethanolamine Lipid Glycerolipid metabolism 
fructose Carbohydrate Fructose, mannose, galactose, starch, and 
105  
sucrose metabolism 
fucose Carbohydrate Aminosugars metabolism 
fumarate Energy Krebs cycle 
gamma-CEHC Cofactors and vitamins Tocopherol metabolism 
gamma-glutamylalanine Peptide gamma-glutamyl 
gamma-glutamylglutamine Peptide gamma-glutamyl 
gamma-glutamylleucine Peptide gamma-glutamyl 
gamma-glutamylmethionine Peptide gamma-glutamyl 
gamma-glutamylphenylalanine Peptide gamma-glutamyl 
gamma-glutamylthreonine* Peptide gamma-glutamyl 
gamma-glutamyltyrosine Peptide gamma-glutamyl 
gamma-glutamylvaline Peptide gamma-glutamyl 
gamma-tocopherol Cofactors and vitamins Tocopherol metabolism 
gluconate Carbohydrate Nucleotide sugars, pentose metabolism 
glucose Carbohydrate 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
glucuronate Carbohydrate 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
glutamate Amino acid Glutamate metabolism 
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glutamine Amino acid Glutamate metabolism 
glutaroylcarnitine (C5) Amino acid Lysine metabolism 
glycerate Carbohydrate 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
glycerol Lipid Glycerolipid metabolism 
glycerol 2-phosphate Xenobiotics Chemical 
glycerol 3-phosphate (G3P) Lipid Glycerolipid metabolism 
glycerophosphorylcholine (GPC) Lipid Glycerolipid metabolism 
glycine Amino acid Glycine, serine and threonine metabolism 
glycochenodeoxycholate Lipid Bile acid metabolism 
glycocholate Lipid Bile acid metabolism 
glycocholenate sulfate* Lipid Bile acid metabolism 
glycodeoxycholate Lipid Bile acid metabolism 
glycolate (hydroxyacetate) Xenobiotics Chemical 
glycolithocholate sulfate* Lipid Bile acid metabolism 
glycoursodeoxycholate Lipid Bile acid metabolism 
glycylphenylalanine Peptide Dipeptide 
glycylvaline Peptide Dipeptide 
heme* Cofactors and vitamins Hemoglobin and porphyrin 
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heptanoate (7:0) Lipid Medium chain fatty acid 
hexadecanedioate (C16) Lipid Fatty acid, dicarboxylate 
hexanoylcarnitine (C6) Lipid Carnitine metabolism 
hippurate Xenobiotics Benzoate metabolism 
histidine Amino acid Histidine metabolism 
homostachydrine* Xenobiotics Food component/Plant 
HWESASXX* Peptide Polypeptide 
hydroxyproline Amino acid Urea cycle; arginine-, proline-, metabolism 
hypoxanthine Nucleotide 
Purine metabolism, (hypo)xanthine/inosine 
containing 
indoleacetate Amino acid Tryptophan metabolism 
indolelactate Amino acid Tryptophan metabolism 
indolepropionate Amino acid Tryptophan metabolism 
inosine Nucleotide 
Purine metabolism, (hypo)xanthine/inosine 
containing 
inositol 1-phosphate (I1P) Lipid Inositol metabolism 
isobutyrylcarnitine (C4) Amino acid Valine, leucine and isoleucine metabolism 
isoleucine Amino acid Valine, leucine and isoleucine metabolism 
isovalerylcarnitine (C5) Amino acid Valine, leucine and isoleucine metabolism 
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kynurenine Amino acid Tryptophan metabolism 
lactate Carbohydrate 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
lathosterol Lipid Sterol/Steroid 
laurate (12:0) Lipid Medium chain fatty acid 
leucine Amino acid Valine, leucine and isoleucine metabolism 
leucylleucine Peptide Dipeptide 
levulinate (4-oxovalerate) Amino acid Valine, leucine and isoleucine metabolism 
linoleate (18:2n6) Lipid Essential fatty acid 
linolenate (18:3n3 or 3n6) Lipid Essential fatty acid 
lysine Amino acid Lysine metabolism 
malate Energy Krebs cycle 
mannitol Carbohydrate 
Fructose, mannose, galactose, starch, and 
sucrose metabolism 
mannose Carbohydrate 
Fructose, mannose, galactose, starch, and 
sucrose metabolism 
margarate (17:0) Lipid Long chain fatty acid 
methionine Amino acid Cysteine, methionine, SAM, taurine metabolism 
methyl palmitate (15 or 2) Lipid Fatty acid, branched 
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methyl palmitate (16:0) Lipid Fatty acid, methyl ester 
methylphosphate Nucleotide Purine and pyrimidine metabolism 
myo-inositol Lipid Inositol metabolism 
myristate (14:0) Lipid Long chain fatty acid 
myristoleate (14:1n5) Lipid Long chain fatty acid 
N6-acetyllysine Amino acid Lysine metabolism 
N-acetylalanine Amino acid Alanine and aspartate metabolism 
N-acetyl-beta-alanine Amino acid Alanine and aspartate metabolism 
N-acetylglycine Amino acid Glycine, serine and threonine metabolism 
N-acetylmethionine Amino acid Cysteine, methionine, SAM, taurine metabolism 
N-acetylneuraminate Carbohydrate Aminosugars metabolism 
N-acetylornithine Amino acid Urea cycle; arginine-, proline-, metabolism 
N-acetylserine Amino acid Glycine, serine and threonine metabolism 
N-acetylthreonine Amino acid Glycine, serine and threonine metabolism 
N-formylmethionine Amino acid Cysteine, methionine, SAM, taurine metabolism 
nicotinamide Cofactors and vitamins Nicotinate and nicotinamide metabolism 
nonadecanoate (19:0) Lipid Long chain fatty acid 
octadecanedioate (C18) Lipid Fatty acid, dicarboxylate 
octanoylcarnitine (C8) Lipid Carnitine metabolism 
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oleate (18:1n9) Lipid Long chain fatty acid 
oleoylcarnitine (C18) Lipid Carnitine metabolism 
ornithine Amino acid Urea cycle; arginine-, proline-, metabolism 
oxalate (ethanedioate) Carbohydrate Glyoxylate and dicarboxylate metabolism 
palmitate (16:0) Lipid Long chain fatty acid 
palmitoleate (16:1n7) Lipid Long chain fatty acid 
palmitoyl sphingomyelin Lipid Sphingolipid 
palmitoylcarnitine (C16) Lipid Carnitine metabolism 
pantothenate (Vitamin B5) Cofactors and vitamins Pantothenate and CoA metabolism 
paraxanthine Xenobiotics Xanthine metabolism 
p-cresol sulfate Amino acid Phenylalanine & tyrosine metabolism 
pelargonate (9:0) Lipid Medium chain fatty acid 
pentadecanoate (15:0) Lipid Long chain fatty acid 
phenol sulfate Amino acid Phenylalanine & tyrosine metabolism 
phenylacetylglutamine Amino acid Phenylalanine & tyrosine metabolism 
phenylalanine Amino acid Phenylalanine & tyrosine metabolism 
phenylalanylleucine* Peptide Dipeptide 
phenylalanylphenylalanine Peptide Dipeptide 
phenyllactate (PLA) Amino acid Phenylalanine & tyrosine metabolism 
111  
phosphate Energy Oxidative phosphorylation 
pipecolate Amino acid Lysine metabolism 
piperine Xenobiotics Food component/Plant 
pregn steroid monosulfate* Lipid Sterol/Steroid 
pregnen-diol disulfate* Lipid Sterol/Steroid 
pregnenolone sulfate Lipid Sterol/Steroid 
proline Amino acid Urea cycle; arginine-, proline-, metabolism 
prolylhydroxyproline Peptide Dipeptide 
propionylcarnitine (C3) Lipid Fatty acid metabolism (also BCAA metabolism) 
pseudouridine Nucleotide Pyrimidine metabolism, uracil containing 
pyridoxate Cofactors and vitamins Vitamin B6 metabolism 
pyroglutamine* Amino acid Glutamate metabolism 
pyroglutamylglycine Peptide Dipeptide 
pyrophosphate (PPi) Energy Oxidative phosphorylation 
pyruvate Carbohydrate 
Glycolysis, gluconeogenesis, pyruvate 
metabolism 
quinate Xenobiotics Food component/Plant 
ribitol Carbohydrate Nucleotide sugars, pentose metabolism 
ribose Carbohydrate Nucleotide sugars, pentose metabolism 
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scyllo-inositol Lipid Inositol metabolism 
sebacate (decanedioate) Lipid Fatty acid, dicarboxylate 
serine Amino acid Glycine, serine and threonine metabolism 
serotonin (5HT) Amino acid Tryptophan metabolism 
S-methylcysteine Amino acid Cysteine, methionine, SAM, taurine metabolism 
sphingomyelin Lipid Sphingolipid 
stachydrine Xenobiotics Food component/Plant 
stearamide Lipid Fatty acid, amide 
stearate (18:0) Lipid Long chain fatty acid 
stearidonate (18:4n3) Lipid Long chain fatty acid 
stearoylcarnitine (C18) Lipid Carnitine metabolism 
suberate (octanedioate) Lipid Fatty acid, dicarboxylate 
succinate Energy Krebs cycle 
succinylcarnitine (C4) Energy Krebs cycle 
sucrose Carbohydrate 
Fructose, mannose, galactose, starch, and 
sucrose metabolism 
taurochenodeoxycholate Lipid Bile acid metabolism 
taurocholenate sulfate* Lipid Bile acid metabolism 
taurodeoxycholate Lipid Bile acid metabolism 
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taurolithocholate 3-sulfate Lipid Bile acid metabolism 
theobromine Xenobiotics Xanthine metabolism 
theophylline Xenobiotics Xanthine metabolism 
threitol Carbohydrate Nucleotide sugars, pentose metabolism 
threonate Cofactors and vitamins Ascorbate and aldarate metabolism 
threonine Amino acid Glycine, serine and threonine metabolism 
triethyleneglycol Xenobiotics Chemical 
trizma acetate Xenobiotics Chemical 
tryptophan Amino acid Tryptophan metabolism 
tryptophan betaine Amino acid Tryptophan metabolism 
tyrosine Amino acid Phenylalanine & tyrosine metabolism 
undecanedioate Lipid Fatty acid, dicarboxylate 
undecanoate (11:0) Lipid Medium chain fatty acid 
urate Nucleotide Purine metabolism, urate metabolism 
urea Amino acid Urea cycle; arginine-, proline-, metabolism 
uridine Nucleotide Pyrimidine metabolism, uracil containing 
vaccenate (18:1n7) Lipid Long chain fatty acid 
valine Amino acid Valine, leucine and isoleucine metabolism 
xanthine Nucleotide Purine metabolism, (hypo)xanthine/inosine 
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containing 
xylonate Carbohydrate Nucleotide sugars, pentose metabolism 
xylose Carbohydrate Nucleotide sugars, pentose metabolism 
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